<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6221633 - Insulin derivatives having a rapid onset of action - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Insulin derivatives having a rapid onset of action"><meta name="DC.contributor" content="Johann Ertl" scheme="inventor"><meta name="DC.contributor" content="Paul Habermann" scheme="inventor"><meta name="DC.contributor" content="Karl Geisen" scheme="inventor"><meta name="DC.contributor" content="Gerhard Seipke" scheme="inventor"><meta name="DC.contributor" content="Aventis Pharma Deutschland Gmbh" scheme="assignee"><meta name="DC.date" content="1998-6-18" scheme="dateSubmitted"><meta name="DC.description" content="The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent."><meta name="DC.date" content="2001-4-24" scheme="issued"><meta name="DC.relation" content="DE:2219635:A1" scheme="references"><meta name="DC.relation" content="DE:3240177:A1" scheme="references"><meta name="DC.relation" content="EP:0018609:A1" scheme="references"><meta name="DC.relation" content="EP:0180920:A2" scheme="references"><meta name="DC.relation" content="EP:0211299:A2" scheme="references"><meta name="DC.relation" content="EP:0214826:A2" scheme="references"><meta name="DC.relation" content="EP:0227938:A2" scheme="references"><meta name="DC.relation" content="EP:0229956:A1" scheme="references"><meta name="DC.relation" content="EP:0305760:A2" scheme="references"><meta name="DC.relation" content="EP:0375437:A2" scheme="references"><meta name="DC.relation" content="EP:0419504:A1" scheme="references"><meta name="DC.relation" content="EP:0600372:A1" scheme="references"><meta name="DC.relation" content="EP:0668292:A2" scheme="references"><meta name="DC.relation" content="EP:0678522:A1" scheme="references"><meta name="DC.relation" content="US:3758683" scheme="references"><meta name="DC.relation" content="US:3868358" scheme="references"><meta name="DC.relation" content="US:4614730" scheme="references"><meta name="DC.relation" content="US:4644057" scheme="references"><meta name="DC.relation" content="US:4731405" scheme="references"><meta name="DC.relation" content="US:4783441" scheme="references"><meta name="DC.relation" content="US:4885164" scheme="references"><meta name="DC.relation" content="US:5101013" scheme="references"><meta name="DC.relation" content="US:5358857" scheme="references"><meta name="DC.relation" content="US:5473049" scheme="references"><meta name="DC.relation" content="US:5597796" scheme="references"><meta name="DC.relation" content="US:5663291" scheme="references"><meta name="DC.relation" content="WO:1983000288:A1" scheme="references"><meta name="DC.relation" content="WO:1990007522:A1" scheme="references"><meta name="DC.relation" content="WO:1992000321:A1" scheme="references"><meta name="citation_reference" content="Berger, Michael, &quot;Towards more physiological insulin therapy in the 1990s-A comment,&quot; Diabetes Research and Clinical Practice, 6 (1989), pp. S25-S31."><meta name="citation_reference" content="Berger, Michael, “Towards more physiological insulin therapy in the 1990s—A comment,” Diabetes Research and Clinical Practice, 6 (1989), pp. S25-S31."><meta name="citation_reference" content="Bolli, Geremia B., &quot;The pharmacokinetic basis of insulin therapy in diabetes mellitus,&quot; Diabetes Research and Clinical Practice, 6 (1989), pp. S3-S16."><meta name="citation_reference" content="Dixon, Dr. G.H. et al., &quot;Regeneration of Insulin Activity From the Separated and Inactive A and B Chains,&quot; Nature, vol. 188, No. 4752 (1960), pp. 721-724."><meta name="citation_reference" content="Drury, P.L. et al., &quot;Diabetic nephropathy,&quot; British Medical Bulletin, vol. 45, No. 1, (1989), pp 127-147."><meta name="citation_reference" content="European Search Report for EP Application 98110889.7-2105, Oct. 14, 1998."><meta name="citation_reference" content="German Search Report for Appln. No. 19726167.1, Nov. 24, 1997."><meta name="citation_reference" content="Home, P.D. et al., &quot;Insuln treatment: a decade of change,&quot; British Medical Bulletin, vol. 45, No. 1, (1989), pp. 92-110."><meta name="citation_reference" content="Kang, Steven et al., &quot;Subcutaneous Insulin Absorption Explained by Insulin&#39;s Physicochemical Properties-Evidence from Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans,&quot; Diabetes Care, vol. 14, No. 11, (1991), pp. 942-948."><meta name="citation_reference" content="Kang, Steven et al., “Subcutaneous Insulin Absorption Explained by Insulin&#39;s Physicochemical Properties—Evidence from Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans,” Diabetes Care, vol. 14, No. 11, (1991), pp. 942-948."><meta name="citation_reference" content="Kemmler, Wolfgang et al., &quot;Studies on the Conversion of Proinsulin to Insulin,&quot; The Journal of Biological Chemistry, vol. 246, No. 22, (1971), pp. 6786-6791."><meta name="citation_reference" content="Kohner, E.M., &quot;Diabetic retinopathy,&quot; British Medical Bulletin,vol. 45, No. 1, (1989), pp. 148-173."><meta name="citation_reference" content="Müller et al., &quot;Insulin Signaling in the Yeast Saccharomyces cerevisiae 1. Stimulation of Glucose Metabolism and Snf 1 Kinase by Human Insulin,&quot; Biochemistry, vol. 37, No. 24, (1998), pp. 8683-8695."><meta name="citation_reference" content="Nathan. et al., &quot;The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus,&quot; The New England Journal of Medicine, vol. 329, No. 14, (1993), pp. 977-986."><meta name="citation_reference" content="Ward, J.D., &quot;Diabetic neuropathy,&quot; British Medical Bulletin, vol. 45, No. 1, (1989), pp. 111-126."><meta name="citation_patent_number" content="US:6221633"><meta name="citation_patent_application_number" content="US:09/099,307"><link rel="canonical" href="http://www.google.com/patents/US6221633"/><meta property="og:url" content="http://www.google.com/patents/US6221633"/><meta name="title" content="Patent US6221633 - Insulin derivatives having a rapid onset of action"/><meta name="description" content="The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent."/><meta property="og:title" content="Patent US6221633 - Insulin derivatives having a rapid onset of action"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("XSvuU9PTG4S7sQSM0YCgDw"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("PRT"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("XSvuU9PTG4S7sQSM0YCgDw"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("PRT"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6221633?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6221633"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=viJUBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6221633&amp;usg=AFQjCNHBIp8_W3w2L5_sxs7F2o7YhNW8Gg" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6221633.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6221633.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6221633" style="display:none"><span itemprop="description">The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention...</span><span itemprop="url">http://www.google.com/patents/US6221633?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6221633 - Insulin derivatives having a rapid onset of action</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6221633 - Insulin derivatives having a rapid onset of action" title="Patent US6221633 - Insulin derivatives having a rapid onset of action"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6221633 B1</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 09/099,307</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Apr 24, 2001</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jun 18, 1998</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jun 20, 1997</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2235443A1">CA2235443A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2235443C">CA2235443C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1195777C">CN1195777C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1203238A">CN1203238A</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE19726167A1">DE19726167A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE19726167B4">DE19726167B4</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE59812316D1">DE59812316D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE122004000049I1">DE122004000049I1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE122004000049I2">DE122004000049I2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0885961A1">EP0885961A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0885961B1">EP0885961B1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">09099307, </span><span class="patent-bibdata-value">099307, </span><span class="patent-bibdata-value">US 6221633 B1, </span><span class="patent-bibdata-value">US 6221633B1, </span><span class="patent-bibdata-value">US-B1-6221633, </span><span class="patent-bibdata-value">US6221633 B1, </span><span class="patent-bibdata-value">US6221633B1</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Johann+Ertl%22">Johann Ertl</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Paul+Habermann%22">Paul Habermann</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Karl+Geisen%22">Karl Geisen</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Gerhard+Seipke%22">Gerhard Seipke</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Aventis+Pharma+Deutschland+Gmbh%22">Aventis Pharma Deutschland Gmbh</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6221633.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6221633.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6221633.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (29),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (15),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (98),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (30),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (14)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6221633&usg=AFQjCNGpjbdnTPSTsVWnnWkY37MLmsxToA">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6221633&usg=AFQjCNEvlwUaveYeP5DQi-5wkjQ517iLPw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6221633B1%26KC%3DB1%26FT%3DD&usg=AFQjCNHx022QfLBi8rFxas55IvO_nWkGYg">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54740694" lang="EN" load-source="patent-office">Insulin derivatives having a rapid onset of action</invention-title></span><br><span class="patent-number">US 6221633 B1</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA72545204" lang="EN" load-source="patent-office"> <div class="abstract">The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(24)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-19.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-19.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-20.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-20.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-21.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-21.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-22.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-22.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6221633-23.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6221633-23.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(64)</span></span></div><div class="patent-text"><div mxw-id="PCLM28626254" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6221633-B1-CLM-00001" class="claim">
      <div class="claim-text">1. An insulin derivative or a physiologically tolerable salt thereof, in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring neutral or acidic amino acid residue.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" id="US-6221633-B1-CLM-00002" class="claim">
      <div class="claim-text">2. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, of formula I <chemistry> <div class="patent-image small-patent-image"> <a href="//patentimages.storage.googleapis.com/US6221633B1/US06221633-20010424-C00002.png"> <img id="EMI-C00002" file="US06221633-20010424-C00002.TIF" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US6221633B1/US06221633-20010424-C00002.png" class="patent-full-image" alt="Figure US06221633-20010424-C00002"> </a> </div> <attachments> <attachment idref="CHEMCDX-00002" attachment-type="cdx" file="US06221633-20010424-C00002.CDX"> </attachment> <attachment idref="CHEMMOL-00002" attachment-type="mol" file="US06221633-20010424-C00002.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">in which</div>
      <div class="claim-text">(A1-A5) are the amino acid residues in the positions A1 to A5 of the A chain of human insulin or animal insulin, </div>
      <div class="claim-text">(A12-A19) are the amino acid residues in the positions A12 to A19 of the A chain of human insulin or animal insulin, </div>
      <div class="claim-text">A21 is Asn, Asp, Gly, Ser, Thr or Ala, </div>
      <div class="claim-text">(B8-B18) are the amino acid residues in the positions B8 to B18 of the B chain of human insulin or animal insulin, </div>
      <div class="claim-text">(B20-B26) are the amino acid residues in the positions B20 to B26 of the B chain of human insulin or animal insulin, </div>
      <div class="claim-text">A8, A9, A10 are the amino acid residues in the positions A8, A9 and A10 of the A chain of human insulin or animal insulin, </div>
      <div class="claim-text">B30 is —OH or the amino acid residue in position B30 of the B chain of human insulin or animal insulin, </div>
      <div class="claim-text">B1 is a phenylalanine residue (Phe) or a hydrogen atom, </div>
      <div class="claim-text">B3 is a naturally occurring basic amino acid residue, </div>
      <div class="claim-text">B27, B28 and B29 are the amino acid residues in the positions B27, B28 and B29 of the B chain of human insulin or animal insulin or in each case are another naturally occurring amino acid residue, where at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is replaced by another naturally occurring amino acid residue which is selected from the group consisting of the neutral or acidic amino acids. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" id="US-6221633-B1-CLM-00003" class="claim">
      <div class="claim-text">3. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>2</b>, wherein</div>
      <div class="claim-text">A8 is alanine (Ala), </div>
      <div class="claim-text">A9 is serine (Ser), </div>
      <div class="claim-text">A10 is valine (Val) and </div>
      <div class="claim-text">B30 is alanine (Ala). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" id="US-6221633-B1-CLM-00004" class="claim">
      <div class="claim-text">4. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>2</b>, wherein</div>
      <div class="claim-text">A8 is threonine (Thr), </div>
      <div class="claim-text">A9 is serine (Ser) and </div>
      <div class="claim-text">A10 is isoleucine (Ile). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" id="US-6221633-B1-CLM-00005" class="claim">
      <div class="claim-text">5. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>4</b>, wherein</div>
      <div class="claim-text">B30 is alanine (Ala). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" id="US-6221633-B1-CLM-00006" class="claim">
      <div class="claim-text">6. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>4</b>, wherein</div>
      <div class="claim-text">B30 is threonine (Thr). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" id="US-6221633-B1-CLM-00007" class="claim">
      <div class="claim-text">7. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>6</b>, wherein</div>
      <div class="claim-text">(A1-A5) are the amino acid residues in the positions A1 to A5 of the A chain of human insulin, </div>
      <div class="claim-text">(A12-A19) are the amino acid residues in the positions A12 to A19 of the A chain of human insulin, </div>
      <div class="claim-text">(B8-B18) are the amino acid residues in the positions B8 to B18 of the B chain of human insulin and </div>
      <div class="claim-text">(B20-B26) are the amino acid residues in the positions B20 to B26 of the B chain of human insulin. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" id="US-6221633-B1-CLM-00008" class="claim">
      <div class="claim-text">8. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein the amino acid residue in position B1 of the B chain is a phenylalanine residue (Phe).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" id="US-6221633-B1-CLM-00009" class="claim">
      <div class="claim-text">9. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein the amino acid residue in position B3 of the B chain is a histidine (His), lysine (Lys) or arginine residue (Arg).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" id="US-6221633-B1-CLM-00010" class="claim">
      <div class="claim-text">10. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>9</b>, wherein the amino acid residue in position B3 of the B chain is a histidine residue (His).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" id="US-6221633-B1-CLM-00011" class="claim">
      <div class="claim-text">11. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>9</b>, wherein the amino acid residue in position B3 of the B chain is an arginine residue (Arg).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" id="US-6221633-B1-CLM-00012" class="claim">
      <div class="claim-text">12. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>9</b>, wherein the amino acid residue in position B3 of the B chain is a lysine residue (Lys).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" id="US-6221633-B1-CLM-00013" class="claim">
      <div class="claim-text">13. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is a naturally occurring amino acid residue which is selected from the group consisting of isoleucine (Ile), aspartic acid (Asp) and glutamic acid (Glu).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" id="US-6221633-B1-CLM-00014" class="claim">
      <div class="claim-text">14. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is a naturally occurring amino acid residue which is selected from the group consisting of the acidic amino acids.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" id="US-6221633-B1-CLM-00015" class="claim">
      <div class="claim-text">15. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>14</b>, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is an aspartic acid residue (Asp).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" id="US-6221633-B1-CLM-00016" class="claim">
      <div class="claim-text">16. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>15</b>, wherein the amino acid residue in position B27 of the B chain is an aspartic acid residue (Asp).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" id="US-6221633-B1-CLM-00017" class="claim">
      <div class="claim-text">17. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>15</b>, wherein the amino acid residue in position B28 of the B chain is an aspartic acid residue (Asp).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" id="US-6221633-B1-CLM-00018" class="claim">
      <div class="claim-text">18. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>15</b>, wherein the amino acid residue in position B29 of the B chain is an aspartic acid residue (Asp).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" id="US-6221633-B1-CLM-00019" class="claim">
      <div class="claim-text">19. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>14</b>, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is a glutamic acid residue (Glu).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" id="US-6221633-B1-CLM-00020" class="claim">
      <div class="claim-text">20. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>19</b>, wherein the amino acid residue in position B27 of the B chain is a glutamic acid residue (Glu).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" id="US-6221633-B1-CLM-00021" class="claim">
      <div class="claim-text">21. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>19</b>, wherein the amino acid residue in position B28 of the B chain is a glutamic acid residue (Glu).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="22" id="US-6221633-B1-CLM-00022" class="claim">
      <div class="claim-text">22. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>19</b>, wherein the amino acid residue in position B29 of the B chain is a glutamic acid residue (Glu).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="23" id="US-6221633-B1-CLM-00023" class="claim">
      <div class="claim-text">23. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>22</b>, wherein the B chain has the sequence</div>
      <div class="claim-text">Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr (SEQ ID NO 3). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="24" id="US-6221633-B1-CLM-00024" class="claim">
      <div class="claim-text">24. A process for the preparation of an insulin derivative as claimed in claim <b>23</b>, comprising</div>
      <div class="claim-text">a) constructing a replicable expression vehicle which contains a DNA sequence which codes for a precursor of the insulin derivative, in which the amino acid residue in position A1 of the A chain is linked to the amino acid residue B30 of the B chain via a peptide chain of the formula II </div>
      <div class="claim-text">
        <maths> <formula-text>—R<sup>1</sup> <sub>n</sub>—Arg—  II </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>1</sup> <sub>n </sub>is a peptide chain having n amino acid residues and n is an integer from 0 to 34, and the B chain is modified by covalent linkage of the amino acid at position B1 to a peptide chain of the formula III </div>
      <div class="claim-text">
        <maths> <formula-text>Met—R<sup>2</sup> <sub>m</sub>—(Arg)<sub>p</sub>—  III </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>2</sup> <sub>m </sub>is a peptide chain having m amino acid residues, m is an integer from 0 to 40 and p is 0, 1 or 2, </div>
      <div class="claim-text">b) expressing the DNA sequence which codes for a precursor of the insulin derivative in a host cell, and </div>
      <div class="claim-text">c) releasing the insulin derivative from its precursor using chemical and/or enzymatic methods, wherein the precursor of the insulin derivative has the sequence </div>
      <div class="claim-text">Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn (SEQ ID NO.: 6). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="25" id="US-6221633-B1-CLM-00025" class="claim">
      <div class="claim-text">25. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein at least one of the amino acid residues in the positions B27 and B28 of the B chain is replaced by a naturally occurring amino acid residue which is selected from the group consisting of the neutral amino acids.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="26" id="US-6221633-B1-CLM-00026" class="claim">
      <div class="claim-text">26. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>25</b>, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is an isoleucine residue (Ile).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="27" id="US-6221633-B1-CLM-00027" class="claim">
      <div class="claim-text">27. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>26</b>, wherein the amino acid residue in position B28 of the B chain is an isoleucine residue (Ile).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="28" id="US-6221633-B1-CLM-00028" class="claim">
      <div class="claim-text">28. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>27</b>, wherein the B chain has the sequence</div>
      <div class="claim-text">Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr IIe Lys Thr (SEQ ID NO 4). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="29" id="US-6221633-B1-CLM-00029" class="claim">
      <div class="claim-text">29. A process for the preparation of an insulin derivative as claimed in claim <b>28</b>, comprising</div>
      <div class="claim-text">a) constructing a replicable expression vehicle which contains a DNA sequence which codes for a precursor of the insulin derivative, in which the amino acid residue in position A1 of the A chain is linked to the amino acid residue B30 of the B chain via a peptide chain of the formula II </div>
      <div class="claim-text">
        <maths> <formula-text>—R<sup>1</sup> <sub>n</sub>—Arg—  II </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>1</sup> <sub>n </sub>is a peptide chain having n amino acid residues and n is an integer from 0 to 34, and the B chain is modified by covalent linkage of the amino acid at position B1 to a peptide chain of the formula III </div>
      <div class="claim-text">
        <maths> <formula-text>Met—R<sup>2</sup> <sub>m</sub>—(Arg)<sub>p</sub>—  III </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>2</sup> <sub>m </sub>is a peptide chain having m amino acid residues, m is an integer from 0 to 40 and p is 0, 1 or 2, </div>
      <div class="claim-text">b) expressing the DNA sequence which codes for a precursor of the insulin derivative in a host cell, and </div>
      <div class="claim-text">c) releasing the insulin derivative from its precursor using chemical and/or enzymatic methods, wherein the precursor of the insulin derivative has the sequence </div>
      <div class="claim-text">Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn (SEQ ID NO.: 7). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="30" id="US-6221633-B1-CLM-00030" class="claim">
      <div class="claim-text">30. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>26</b>, wherein the amino acid residue in position B27 of the B chain is an isoleucine residue (Ile).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="31" id="US-6221633-B1-CLM-00031" class="claim">
      <div class="claim-text">31. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>30</b>, wherein the B chain has the sequence</div>
      <div class="claim-text">Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr lIe Pro Lys Thr (SEQ ID NO 5). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="32" id="US-6221633-B1-CLM-00032" class="claim">
      <div class="claim-text">32. A process for the preparation of an insulin derivative as claimed in claim <b>31</b>, comprising</div>
      <div class="claim-text">a) constructing a replicable expression vehicle which contains a DNA sequence which codes for a precursor of the insulin derivative, in which the amino acid residue in position A1 of the A chain is linked to the amino acid residue B30 of the B chain via a peptide chain of the formula II </div>
      <div class="claim-text">
        <maths> <formula-text>—R<sup>1</sup> <sub>n</sub>—Arg—  II </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>1</sup> <sub>n </sub>is a peptide chain having n amino acid residues and n is an integer from 0 to 34, and the B chain is modified by covalent linkage of the amino acid at position B1 to a peptide chain of the formula III </div>
      <div class="claim-text">
        <maths> <formula-text>Met—R<sup>2</sup> <sub>m</sub>—(Arg)<sub>p</sub>—  III </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>2</sup> <sub>m </sub>is a peptide chain having m amino acid residues, m is an integer from 0 to 40 and p is 0, 1 or 2, </div>
      <div class="claim-text">b) expressing the DNA sequence which codes for a precursor of the insulin derivative in a host cell, and </div>
      <div class="claim-text">c) releasing the insulin derivative from its precursor using chemical and/or enzymatic methods, wherein the precursor of the insulin derivative has the sequence </div>
      <div class="claim-text">Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Ile Pro Lys Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Lcu Tyr Gln Leu Glu Asn Tyr Cys Asn (SEQ ID NO.: 8). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="33" id="US-6221633-B1-CLM-00033" class="claim">
      <div class="claim-text">33. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein the amino acid residue in position A21 of the A chain is an asparagine residue (Asp).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="34" id="US-6221633-B1-CLM-00034" class="claim">
      <div class="claim-text">34. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>33</b>, wherein the A chain has the sequence</div>
      <div class="claim-text">Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asp (SEQ ID NO.: 9) </div>
      <div class="claim-text">and the B chain has the sequence</div>
      <div class="claim-text">Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr (SEQ ID NO.: 10). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="35" id="US-6221633-B1-CLM-00035" class="claim">
      <div class="claim-text">35. A process for the preparation of an insulin derivative as claimed in claim <b>33</b>, comprising</div>
      <div class="claim-text">a) constricting a replicable, expression vehicle which contains a DNA sequence which codes for a precursor of the insulin derivative, in which the amino acid residue in position A1 of the A chain is linked to the amino acid residue B30 of the B chain via a peptide chain of the formula II </div>
      <div class="claim-text">
        <maths> <formula-text>—R<sup>1</sup> <sub>n</sub>—Arg—  II </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>1</sup> <sub>n </sub>is a peptide chain having n amino acid residues and n is an integer from 0 to 34, and the B chain is modified by covalent linkage of the amino acid at position B1 to a peptide chain of the formula III </div>
      <div class="claim-text">
        <maths> <formula-text>Met—R<sup>2</sup> <sub>m</sub>—(Arg)<sub>p</sub>—  III </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>2</sup> <sub>m </sub>is a peptide chain having m amino acid residues, m is an integer from 0 to 40 and p is 0, 1 or 2, </div>
      <div class="claim-text">b) expressing the DNA sequence which codes for a precursor of the insulin derivative in a host cell, and </div>
      <div class="claim-text">c) releasing the insulin derivative from its precursor using chemical and/or enzymatic methods, wherein the precursor of the insulin derivative has the sequence </div>
      <div class="claim-text">Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asp (SEQ ID No.: 11). </div>
    </div>
    </div> <div class="claim-dependent"> <div num="36" id="US-6221633-B1-CLM-00036" class="claim">
      <div class="claim-text">36. A pharmaceutical preparation, which comprises at least one insulin derivative and/or a physiologically tolerable salt thereof as claimed in claim <b>1</b>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="37" id="US-6221633-B1-CLM-00037" class="claim">
      <div class="claim-text">37. A pharmaceutical preparation as claimed in claim <b>36</b>, which comprises the insulin derivative and/or the physiologically tolerable salt thereof in dissolved, amorphous and/or crystalline form.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="38" id="US-6221633-B1-CLM-00038" class="claim">
      <div class="claim-text">38. A pharmaceutical preparation as claimed in claim <b>36</b>, which further comprises a depot auxiliary.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="39" id="US-6221633-B1-CLM-00039" class="claim">
      <div class="claim-text">39. A pharmaceutical preparation as claimed in claim <b>38</b>, wherein the depot auxiliary is protamine sulfate, where the insulin derivative and/or the physiologically tolerable salt thereof is present with the protamine sulfate in a cocrystallizate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="40" id="US-6221633-B1-CLM-00040" class="claim">
      <div class="claim-text">40. A method for the treatment of diabetes mellitus comprising administering an effective amount of the pharmaceutical preparation of claim <b>36</b>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="41" id="US-6221633-B1-CLM-00041" class="claim">
      <div class="claim-text">41. An injectable solution having insulin activity, comprising the pharmaceutical preparation as claimed in claim <b>36</b> in dissolved form.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="42" id="US-6221633-B1-CLM-00042" class="claim">
      <div class="claim-text">42. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein asparagine (Asn) in position 21 of the A chain is replaced by Asp, Gly, Ser, Thr or Ala.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="43" id="US-6221633-B1-CLM-00043" class="claim">
      <div class="claim-text">43. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein phenylalanine (Phe) in position B1 of the B chain is absent.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="44" id="US-6221633-B1-CLM-00044" class="claim">
      <div class="claim-text">44. An insulin derivative or a physiologically tolerable salt thereof as claimed in claim <b>1</b>, wherein the amino acid residue in position B30 of the B chain is absent.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="45" id="US-6221633-B1-CLM-00045" class="claim">
      <div class="claim-text">45. A process for the preparation of an insulin derivative or of a physiologically tolerable salt thereof as claimed in claim <b>1</b>, comprising</div>
      <div class="claim-text">a) constructing a replicable, expression vehicle which contains a DNA sequence which codes for a precursor of the insulin derivative, in which the amino acid residue in position A1 of the A chain is linked to the amino acid residue B30 of the B chain via a peptide chain of the formula II </div>
      <div class="claim-text">
        <maths> <formula-text>—R<sup>1</sup> <sub>n−</sub>Arg—  II </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>1</sup> <sub>n </sub>is a peptide chain having n amino acid residues and n is an integer from 0 to 34, and the B chain is modified by covalent linkage of the amino acid at position B1 to a peptide chain of the formula III </div>
      <div class="claim-text">
        <maths> <formula-text>Met—R<sup>2</sup> <sub>m−</sub>(Arg)<sub>p−</sub>  III </formula-text> </maths> </div>
      <div class="claim-text"> in which R<sup>2</sup> <sub>m </sub>is a peptide chain having m amino acid residues, m is an integer from 0 to 40 and p is 0, 1 or 2, </div>
      <div class="claim-text">b) expressing the DNA sequence which codes for a precursor of the insulin derivative in a host cell, and </div>
      <div class="claim-text">c) releasing the insulin derivative from its precursor using chemical and/or enzymatic methods. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="46" id="US-6221633-B1-CLM-00046" class="claim">
      <div class="claim-text">46. The process as claimed in claim <b>45</b>, wherein the host cell is a bacterium.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="47" id="US-6221633-B1-CLM-00047" class="claim">
      <div class="claim-text">47. The process as claimed in claim <b>46</b>, wherein the bacterium is <i>E. coli. </i> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="48" id="US-6221633-B1-CLM-00048" class="claim">
      <div class="claim-text">48. The process as claimed in claim <b>45</b>, wherein the host cell is a yeast.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="49" id="US-6221633-B1-CLM-00049" class="claim">
      <div class="claim-text">49. The process as claimed in claim <b>48</b>, wherein the yeast is <i>Saccharomyces cerevisiae. </i> </div>
    </div>
    </div> <div class="claim"> <div num="50" id="US-6221633-B1-CLM-00050" class="claim">
      <div class="claim-text">50. A precursor of an insulin derivative, wherein the precursor has a sequence selected from the group consisting of SEQ ID NO.: 11, SEQ ID NO.:6, SEQ ID NO.:8, and SEQ ID NO.:7.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="51" id="US-6221633-B1-CLM-00051" class="claim">
      <div class="claim-text">51. The precursor of claim <b>50</b>, wherein the precursor has the sequence of SEQ ID NO.:6.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="52" id="US-6221633-B1-CLM-00052" class="claim">
      <div class="claim-text">52. The precursor of claim <b>50</b>, wherein the precursor has the sequence of SEQ ID NO.:8.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="53" id="US-6221633-B1-CLM-00053" class="claim">
      <div class="claim-text">53. The precursor of claim <b>50</b>, wherein the precursor has the sequence of SEQ ID NO.:7.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="54" id="US-6221633-B1-CLM-00054" class="claim">
      <div class="claim-text">54. The precursor of claim <b>50</b>, wherein the precursor has the sequence of SEQ ID NO.:11.</div>
    </div>
    </div> <div class="claim"> <div num="55" id="US-6221633-B1-CLM-00055" class="claim">
      <div class="claim-text">55. An isolated or purified nucleic acid comprising a sequence which codes for a precursor of an insulin derivative having a sequence selected from the group consisting of SEQ ID NO.:11, SEQ ID NO.:6, SEQ ID NO.8, and SEQ ID NO.:7.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="56" id="US-6221633-B1-CLM-00056" class="claim">
      <div class="claim-text">56. The isolated or purified nucleic acid of claim <b>55</b>, having the sequence of SEQ ID NO.11.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="57" id="US-6221633-B1-CLM-00057" class="claim">
      <div class="claim-text">57. An expression vehicle comprising a nucleic acid as claimed in claim <b>56</b>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="58" id="US-6221633-B1-CLM-00058" class="claim">
      <div class="claim-text">58. A host cell which is transformed using an expression vehicle as claimed in claim <b>57</b>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="59" id="US-6221633-B1-CLM-00059" class="claim">
      <div class="claim-text">59. The isolated or purified nucleic acid of claim <b>55</b>, having the sequence of SEQ ID NO.:6.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="60" id="US-6221633-B1-CLM-00060" class="claim">
      <div class="claim-text">60. An expression vehicle comprising a nucleic acid as claimed in claim <b>59</b>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="61" id="US-6221633-B1-CLM-00061" class="claim">
      <div class="claim-text">61. The isolated or purified nucleic acid of claim <b>55</b>, having the sequence of SEQ ID NO.:8.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="62" id="US-6221633-B1-CLM-00062" class="claim">
      <div class="claim-text">62. An expression vehicle comprising a nucleic acid as claimed in claim <b>61</b>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="63" id="US-6221633-B1-CLM-00063" class="claim">
      <div class="claim-text">63. The isolated or purified nucleic acid of claim <b>55</b>, having the sequence of SEQ ID NO.:7.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="64" id="US-6221633-B1-CLM-00064" class="claim">
      <div class="claim-text">64. An expression vehicle comprising a nucleic acid as claimed in claim <b>63</b>.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES54532971" lang="EN" load-source="patent-office" class="description">
    <p>The present invention relates to insulin derivatives which, in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus.</p>
    <p>Approximately 120 million people worldwide suffer from diabetes mellitus. Among these are approximately 12 million type I diabetics, for whom the administration of insulin is the only therapy possible at present. The affected people are assigned insulin injections, as a rule several times daily, for life. Although type II diabetes, from which approximately 100 million people suffer, is not fundamentally accompanied by an insulin deficiency, in a large number of cases, however, treatment with insulin is regarded as the most favorable or only possible form of therapy.</p>
    <p>With increasing length of the disease, a large number of the patients suffer from so-called diabetic late complications. These are essentially micro- and macrovascular damage, which depending on the type and extent, result in kidney failure, blindness, loss of extremities or an increased risk of heart/circulation disorders.</p>
    <p>As a cause, chronically increased blood glucose levels are primarily held responsible, since even with careful adjustment of the insulin therapy a normal blood glucose profile, such as would correspond to physiological regulation, is not achieved (Ward, J. D. (1989) British Medical Bulletin 45, 111-126; Drury, P. L. et al. (1989) British Medical Bulletin 45, 127-147; Kohner, E. M. (1989) British Medical Bulletin 45, 148-173)</p>
    <p>In healthy people, insulin secretion is closely dependent on the glucose concentration of the blood. Increased glucose levels, such as occur after meals, are rapidly compensated by an increased release of insulin. In the fasting state, the plasma insulin level falls to a basal value, which is sufficient to guarantee a continuous supply of insulin-sensitive organs and tissue with glucose. An optimization of the therapy, the so-called intensified insulin therapy, is today primarily aimed at keeping variations in the blood glucose concentration, especially deviations upward, as low as possible (Bolli, G. B. (1989) Diabetes Res. Clin. Pract. 6, p. 3-p. 16; Berger, M. (1989) Diabetes Res. Clin. Pract. 6, p. 25-p. 32). This leads to a significant decrease in the occurrence and the progression of diabetic late damage (The Diabetes Control and Complications Trial Research Group (1993) N. Engl. J. Med. 329, 977-986).</p>
    <p>From the physiology of insulin secretion, it can be deduced that for an improved, intensified insulin therapy using subcutaneously administered preparations, two insulin preparations having different pharmacodynamics are needed. To compensate the blood glucose rise after meals, the insulin must flow in rapidly and must only act for a few hours. For the basal supply, in particular in the night, a preparation should be available which acts for a long time, has no pronounced maximum and only infuses very slowly.</p>
    <p>The preparations based on human and animal insulins only fulfill the demands of an intensified insulin therapy, however, in a restricted manner. After subcutaneous administration, rapidly acting insulins (unmodified insulins) pass too slowly into the blood and to the site of action and have too long an overall duration of action. The result is that the postprandial glucose levels are too high and the blood glucose begins to fall severely several hours after the meal (Kang, S. et al. (1991) Diabetes Care 14, 142-148; Home, P. J. et al. (1989) British Medical Bulletin 45, 92-110; Bolli, G. B. (1989) Diabetes Res. Clin. Pract. 6, p. 3-p. 16). The available basal insulins in turn, especially NPH insulins, have too short a duration of action and have a too severely pronounced maximum.</p>
    <p>Beside the possibility of affecting the profile of action by means of pharmaceutical principles, the alternative presents itself today of designing insulin derivatives, with the aid of genetic engineering, which achieve specific properties such as onset and duration of action solely by means of their structural properties. By the use of suitable insulin derivatives, a significantly better adjustment of the blood glucose more closely adapted to the natural conditions could therefore be achieved.</p>
    <p>Insulin derivatives having an accelerated onset of action are described in EP 0 214 826, EP 0 375 437 and EP 0 678 522. EP 0 214 826 relates, inter alia, to substitutions of B27 and B28, but not in combination with the substitution of B3. EP 0 678 522 describes insulin derivatives which have various amino acids, preferably proline, but not glutamic acid, in the position B29. EP 0 375 437 encompasses insulin derivatives having lysine or arginine in B28, which can optionally be additionally modified in B3 and/or A21.</p>
    <p>EP 0 419 504 discloses insulin derivatives which are protected against chemical modifications by changing asparagine in B3 and at least one further amino acid in the positions A5, A15, A18 or A21. Combinations with modifications in positions B27, B28 or B29 are, however, not described. An indication that these compounds have modified pharmacodynamics resulting in a more rapid onset of action is not given.</p>
    <p>WO 92/00321 describes insulin derivatives in which at least one amino acid of the positions B1-B6 is replaced by lysine or arginine. According to WO 92/00321, insulins of this type have a prolonged action. Combinations with modifications of the positions B27, 28, 29, however, are not disclosed.</p>
    <heading>BRIEF DESCRIPTION OF THE DRAWING</heading> <p>The FIGURE shows the pharmacodynamics of insulin and derivatives according to the invention after subcutaneous administration to dogs. The mean glucose infusion rate from the time of injection (T=0) through 240 minutes is shown for insulin and selected derivatives according to the invention.</p>
    <p>The object of the present invention is to prepare insulin derivatives which after administration, in particular after subcutaneous administration, have an onset of action which is accelerated in comparison with human insulin.</p>
    <p>Insulin derivatives are derivatives of naturally occurring insulins, namely human insulin (see SEQ ID NO 1=A chain of human insulin; see SEQ ID NO 2=B chain of human insulin, sequence listing) or animal insulins which differ from the corresponding, otherwise identical naturally occurring insulin by substitution of at least one naturally occurring amino acid residue and/or addition of at least one amino acid residue and/or organic residue.</p>
    <p>It is further an object of the present invention to provide a process for the preparation of the insulin derivatives having the property mentioned, the corresponding intermediates and their precursors.</p>
    <p>The object is achieved by an insulin derivative or a physiologically tolerable salt thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.</p>
    <p>Preferably, the insulin derivative or its physiologically tolerable salt is of formula I <chemistry> <div class="patent-image small-patent-image"> <a href="//patentimages.storage.googleapis.com/US6221633B1/US06221633-20010424-C00001.png"> <img id="EMI-C00001" file="US06221633-20010424-C00001.TIF" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US6221633B1/US06221633-20010424-C00001.png" class="patent-full-image" alt="Figure US06221633-20010424-C00001"> </a> </div> <attachments> <attachment idref="CHEMCDX-00001" attachment-type="cdx" file="US06221633-20010424-C00001.CDX"> </attachment> <attachment idref="CHEMMOL-00001" attachment-type="mol" file="US06221633-20010424-C00001.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>in which</p>
    <p>(A1-A5) are the amino acid residues in the positions A1 to A5 of the A chain of human insulin (cf. SEQ ID NO 1) or animal insulin,</p>
    <p>(A12-A19) are the amino acid residues in the positions A12 to A19 of the A chain of human insulin (cf. SEQ ID NO 1) or animal insulin,</p>
    <p>(B8-B18) are the amino acid residues in the positions B8 to B18 of the B chain of human insulin (cf. SEQ ID NO 2) or animal insulin,</p>
    <p>(B20-B26) are the amino acid residues in the positions B20 to B26 of the B chain of human insulin (cf. SEQ ID NO 2) or animal insulin,</p>
    <p>A8, A9, A10 are the amino acid residues in the positions A8, A9 and A10 of the A chain of human insulin (cf. SEQ ID NO 1) or animal insulin,</p>
    <p>A21 is Asn, Asp, Gly, Ser, Thr or Ala,</p>
    <p>B30 is —OH or the amino acid residue in position B30 of the B chain of human insulin (cf. SEQ ID NO 2) or animal insulin,</p>
    <p>B1 is a phenylalanine residue (Phe) or a hydrogen atom,</p>
    <p>B3 is a naturally occurring basic amino acid residue,</p>
    <p>B27, B28 and B29 are the amino acid residues in the positions B27, B28 and B29 of the B chain of human insulin (cf. SEQ ID NO 2) or animal insulin or in each case are another naturally occurring amino acid residue, where at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is replaced by another naturally occurring amino acid residue.</p>
    <p>Of the twenty naturally occurring amino acids which are genetically encodable, the amino acids glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), serine (Ser), threonine (Thr), cysteine (Cys), methionine (Met), asparagine (Asn), glutamine (Gln), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp) and proline (Pro) are designated here as neutral amino acids, the amino acids arginine (Arg), lysine (Lys) and histidine (His) are designated as basic amino acids and the amino acids aspartic acid (Asp) and glutamic acid (Glu) are designated as acidic amino acids.</p>
    <p>Preferably, the insulin derivative or its physiologically tolerable salt according to the present invention is a derivative of bovine insulin, porcine insulin or human insulin, namely an insulin derivative or a physiologically tolerable salt thereof of the formula 1, which is distinguished in that</p>
    <p>A8 is alanine (Ala),</p>
    <p>A9 is serine (Ser),</p>
    <p>A10 is valine (Val) and</p>
    <p>B30 is alanine (Ala) (amino acid residues A8 to A10 and B30 of bovine insulin),</p>
    <p>A8 is threonine (Thr),</p>
    <p>A9 is serine (Ser) and</p>
    <p>A10 is isoleucine (Ile) (amino acid residues A8 to A10 of the insulins of man or pigs), where</p>
    <p>B30 is alanine (Ala) (amino acid residue B30 of porcine insulin) or</p>
    <p>B30 is threonine (Thr) (amino acid residue B30 of human insulin, cf. SEQ ID NO 2).</p>
    <p>Particularly preferably, an insulin derivative or a physiologically tolerable salt thereof of the formula I with the amino acid residues A8 to A10 and B30 of human insulin is one which is furthermore distinguished in that</p>
    <p>(A1-A5) are the amino acid residues in the positions A1 to A5 of the A chain of human insulin (cf. SEQ ID NO 1),</p>
    <p>(A12-A19) are the amino acid residues in the positions A12 to A19 of the A chain of human insulin (cf. SEQ ID NO 1),</p>
    <p>(B8-B18) are the amino acid residues in the positions B8 to B18 of the B chain of human insulin (cf. SEQ ID NO 2) and</p>
    <p>(B20-B26) are the amino acid residues in the positions B20 to B26 of the B chain of human insulin (cf. SEQ ID NO 2).</p>
    <p>Further preferred embodiments of the present invention are an insulin derivative or a physiologically tolerable salt thereof of the formula 1, wherein the amino acid residue in position B1 of the B chain is a phenylalanine residue (Phe) or</p>
    <p>an insulin derivative or a physiologically tolerable salt thereof of the formula 1, wherein the amino acid residue in position B3 of the B chain is a histidine (His), lysine (Lys) or arginine residue (Arg).</p>
    <p>Further preferred embodiments of the present invention are an insulin derivative or a physiologically tolerable salt thereof of the formula 1, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is replaced by a naturally occurring amino acid residue which is selected from the group consisting of the neutral or of the acidic amino acids,</p>
    <p>an insulin derivative or a physiologically tolerable salt thereof of the formula I, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is a naturally occurring amino acid residue which is selected from the group consisting of isoleucine (Ile), aspartic acid (Asp) and glutamic acid (Glu), preferably wherein at least one of the amino acid residues in the positions B27, B28 of the B chain is replaced by a naturally occuring amino acid residue which is selected from the group consisting of the neutral amino acids, or particularly preferably wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is an isoleucine residue (Ile), or</p>
    <p>an insulin derivative or a physiologically tolerable salt thereof of the formula I, wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is a naturally occurring amino acid residue which is selected from the group consisting of the acidic amino acids, preferably wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is an aspartic acid residue (Asp), preferably wherein the amino acid residue in position B27 or B28 of the B chain is an aspartic acid residue (Asp), or wherein at least one of the amino acid residues in the positions B27, B28 and B29 of the B chain is a glutamic acid residue (Glu).</p>
    <p>A preferred embodiment of the present invention is also an insulin derivative or a physiologically tolerable salt thereof of the formula I, wherein the amino acid residue in position B29 of the B chain is an aspartic acid residue (Asp).</p>
    <p>Further preferred embodiments are an insulin derivative or a physiologically tolerable salt thereof of the formula I, wherein the amino acid residue in position B27 of the B chain is a glutamic acid residue (Glu),</p>
    <p>an insulin derivative or a physiologically tolerable salt thereof of the formula I, wherein the amino acid residue in position B28 of the B chain is a glutamic acid residue (Glu), or</p>
    <p>an insulin derivative or a physiologically tolerable salt thereof of the formula I, wherein the amino acid residue in position B29 of the B chain is a glutamic acid residue (Glu).</p>
    <p>Very particularly preferably, an insulin derivative or a physiologically tolerable salt thereof is one which is distinguished in that the B chain has the sequence</p>
    <p>Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr</p>
    <p>(SEQ ID NO 3), for example Lys (B3), Glu (B29)-human insulin, or</p>
    <p>an insulin derivative or a physiologically tolerable salt thereof which is distinguished in that the amino acid residue in position B27 of the B chain is an isoleucine residue (Ile), preferably an insulin derivative or a physiologically tolerable salt thereof which is distinguished in that the B chain has the sequence</p>
    <p>Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Ile Pro Lys Thr</p>
    <p>(SEQ ID NO 5), for example Lys (B3), Ile (B27)-human insulin, or</p>
    <p>an insulin derivative or a physiologically tolerable salt thereof of the formula I, wherein the amino acid residue in position B28 of the B chain is an isoleucine residue (Ile), preferably an insulin derivative or a physiologically tolerable salt thereof which is distinguished in that the B chain has the sequence</p>
    <p>Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr</p>
    <p>(SEQ ID NO 4), for example Lys (B3), Ile (B28)-human insulin.</p>
    <p>Particularly preferably, an insulin derivative or a physiologically tolerable salt thereof of the formula I, which is distinguished in that the amino acid residue in position B28 of the B chain is an isoleucine residue (Ile) and the amino acid residue in position A21 is an asparagine residue (Asp), is preferably one wherein the A chain has the sequence</p>
    <p>Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Tyr Gln Leu Glu Asn Tyr Cys Asp (SEQ ID NO.: 9)</p>
    <p>and the B chain has the sequence</p>
    <p>Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Pyr Thr Ile Lys Thr (SEQ ID NO.: 10)</p>
    <p>(Lys (B3), Ile (B28), Asp (A21)-human insulin).</p>
    <p>The insulin derivatives of the formula I can preferably be prepared by genetic engineering.</p>
    <p>The object set at the outset is accordingly further achieved by a process for the preparation of an insulin derivative or of a physiologically tolerable salt thereof of the formula I, comprising the construction of a replicable expression vehicle which contains a DNA sequence which codes for a precursor of the insulin derivative in which the amino acid residue in position A1 of the A chain is linked to the amino acid residue B30 of the B chain via a peptide chain of the formula II</p>
    <p>
      <maths> <formula-text>—R<sup>1</sup> <sub>n</sub>—Arg—  II</formula-text> </maths> </p>
    <p>in which R<sup>1</sup> <sub>n </sub>is a peptide chain having n amino acid residues and n is an integer from 0 to 34, and the B chain is prolonged in position B1 by a peptide chain of the formula III</p>
    <p>
      <maths> <formula-text>Met-R<sup>2</sup> <sub>m</sub>—(Arg)<sub>p</sub>—  III</formula-text> </maths> </p>
    <p>in which R<sup>2</sup> <sub>m </sub>is a peptide chain having m amino acid residues, m is an integer from 0 to 40, preferably from 0 to 9, and p is 0, 1 or 2, where for p=0 the peptide chain R<sup>2</sup> <sub>m </sub>preferably ends with Lys, expression in a host cell and release of the insulin derivative from its precursor using chemical and/or enzymatic methods.</p>
    <p>Preferably, the process is one wherein the host cell is a bacterium, particularly preferably one wherein the bacterium is <i>E. coli. </i> </p>
    <p>Preferably, the process is one wherein the host cell is a yeast, particularly preferably one wherein the yeast is <i>Saccharomyces cerevisiae. </i> </p>
    <p>For the preparation of an insulin derivative having the amino acid sequences SEQ ID NO.: 9 (A chain) and SEQ ID NO.: 10 (B chain), the precursor of this insulin derivative preferably has the sequence</p>
    <p>Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Ley Glu Asn Tyr Cys Asp (SEQ ID NO.: 11),</p>
    <p>a Lys (B3), Ile (B28), Asp (A21 )-preproinsuLin.</p>
    <p>For the preparation of an insulin derivative having the amino acid sequence SEQ ID NO 3, the precursor of this insulin derivative preferably has the sequence</p>
    <p>Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Va Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn (Lys (B3), Glu (829)-preproinsulin)</p>
    <p>(SEQ ID NO 6).</p>
    <p>For the preparation of an insulin derivative having the amino acid sequence SEQ ID NO 5, the precursor of this insulin derivative preferably has the sequence</p>
    <p>Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Ile Pro Lys Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Gu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn (Lys (B3), Ile (B27)-preproinsulin)</p>
    <p>(SEQ ID NO 8).</p>
    <p>For the preparation of an insulin derivative having the amino acid sequence SEQ ID NO 4, the precursor of this insulin derivative preferably has the sequence</p>
    <p>Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr Arg Arg Glu Ala Glu Asp Pro Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn (Lys (B3), Ile (B28)-preproinsulin)</p>
    <p>(SEQ ID NO 7).</p>
    <p>The present invention accordingly also relates to said precursors of the preferred insulin derivatives, namely the peptides having the sequence numbers SEQ ID NO.: 11, SEQ ID NO 6, SEQ ID NO 7 and SEQ ID NO 8, the DNA sequences which code for said precursors, the expression vehicles which comprise these DNA sequences and the host cells which are transformed using these expression vehicles.</p>
    <p>The insulin derivatives of the formula I are mainly prepared by genetic engineering by means of site-directed mutagenesis according to standard methods.</p>
    <p>To do this, a gene structure coding for the desired insulin derivative of the formula I is constructed and expressed in a host cell—preferably in a bacterium such as <i>E. coli </i>or a yeast, in particular <i>Saccharomyces cerevisiae</i>—and—if the gene structure codes for a fusion protein—the insulin derivative of the formula I is released from the fusion protein; analogous methods are described, for example, in EP-A-0 211 299, EP-A-0 227 938, EP-A-0 229 998, EP-A-0 286 956 and the DE patent application P 38 21 159.</p>
    <p>The removal of the fusion protein component can be carried out chemically by cell disruption by means of cyanogen halide (see EP-A-0 180 920).</p>
    <p>In the preparation by means of a preproinsulin precursor which has a fusion protein component (presequence) according to U.S. Pat. No. 5,358,857, the removal of the fusion protein component takes place in a later stage together with the removal of the C peptide.</p>
    <p>The insulin precursor is then subjected to oxidative sulfitolysis according to the method described, for example, by R. C. Marshall and A. S. Inglis in “Practical Protein Chemistry—A Handbook” (Publisher A. Darbre) 1986, pages 49-53 and then renatured in the presence of a thiol with formation of the correct disulfide bridges, e.g. according to the method described by G. H. Dixon and A. C. Wardlow in Nature (1960), pages 721-724. The insulin precursors, however, can also be folded directly (EP-A-0 600 372; EP-A-0 668 292).</p>
    <p>The C peptide is removed by means of tryptic cleavage—e.g. according to the method of Kemmler et al., J. B. C. (1971), pages 6786-6791 and the insulin derivative of the formula I is purified by means of known techniques such as chromatography—e.g. EP-A-0 305 760—and crystallization.</p>
    <p>If n in formula II is 0, tryptic cleavage serves to sever the peptide bond between A and B chains.</p>
    <p>In this process, the B chain C terminal ends with arginine or two arginine residues. These can be removed enzymatically by means of carboxy-peptidase B.</p>
    <p>The insulin derivatives according to the invention have full biological activity. This was shown by intravenous administration to rabbits and the blood glucose fall resulting therefrom (Examples 5 and 6).</p>
    <p>The more rapid onset of action after subcutaneous administration was shown in fasting dogs using the euglycemic clamp technique (Example 7). 0.3 IU/kg was administered. The reference preparation was human insulin. In the clamp technique, the blood glucose value is measured at short time intervals after insulin injection and exactly the amount of glucose to compensate the fall is infused. This has the advantage that no counter-regulation occurs with the animals, as would be the case with a severe fall in the blood glucose after the administration of insulin. The amount and the time course of the infused glucose characterize the action of the insulin. Lys(B3), Glu(B29)—(SEQ ID NO 3) and Lys(B3), Ile(B28)—(SEQ ID NO 4) insulin have a clearly more rapid onset of action than human insulin. The maximum action (glucose infusion rate) is achieved after 100 minutes with human insulin, after 80 minutes, however, with Lys(B3), Glu(B29)-insulin (SEQ ID NO 3) and already after 60 minutes with Lys(B3)—, Ile(B28)-insulin (SEQ ID NO 4). Therefore these analogs, when they are injected shortly before a meal, should compensate the postprandial rise in the blood glucose better than human insulin.</p>
    <p>The insulin derivatives described are therefore suitable both for the therapy of type I and of type II diabetes mellitus, preferably in combination with a basal insulin.</p>
    <p>The present invention therefore also relates to the use of the insulin derivative and/or its physiologically tolerable salt of the formula I for the production of a pharmaceutical preparation which has an insulin activity with a rapid onset of action.</p>
    <p>A suitable carrier medium which is physiologically acceptable and compatible with the insulin derivative is a sterile aqueous solution which is made isotonic with blood in the customary manner, e.g. by means of glycerol, sodium chloride, glucose, and in addition contains one of the customary preservatives, e.g. phenol, m-cresol or p-hydroxybenzoic acid ester. The carrier medium can additionally contain a buffer substance, e.g. sodium acetate, sodium citrate, sodium phosphate. For adjustment of the pH, dilute acids (typically HCl) or alkalis (typically NaOH) are used. The preparation can furthermore contain zinc ions.</p>
    <p>The insulin derivatives can be employed in the pharmaceutical preparations even in the form of their physiologically tolerable salts, as alkali metal or as ammonium salts. Any desired proportion of one or more insulin derivatives of the formula I or an insulin derivative of the formula I can be present in a mixture of other of these insulin derivatives independently of one another in each case in dissolved, amorphous and/or crystalline form.</p>
    <p>It is sometimes advantageous to add to the preparation according to the invention a suitable amount of a suitable stabilizer which prevents the precipitation of protein under thermomechanical stress on contact with various materials. Such stabilizers are disclosed, for example, in EP-A-18609, DE-A 32 40 177 or in WO-83/00288.</p>
    <p>The present invention further relates to a pharmaceutical preparation which comprises at least one insulin derivative and/or a physiologically tolerable salt thereof of the formula I, preferably in dissolved, amorphous and/or crystalline form.</p>
    <p>The insulin derivatives according to the invention have a rapid onset of action. In practical insulin therapy, it is customary under certain circumstances to mix rapid-acting insulins with preparations which contain a depot auxiliary (e.g. NPH insulin). Depending on the composition, preparations result from this whose profiles of action correspond to the superimposed individual profiles provided the individual components in the mixture are stable and are not mutually affected. When mixing an insulin derivative with human NPH insulin, however, it is to be expected that, particularly on long-term storage, an exchange takes place between the dissolved derivative and the crystalline NPH insulin. As a result of this both the pharmacodynamics of the depot insulin and those of the dissolved rapidly acting insulin are changed in an unforeseeable manner. In order to avoid this, it is sensible to prepare the rapidly acting derivative using a depot auxiliary—for example as NPH insulin. This depot form of the insulin derivative can then be mixed as desired with the dissolved rapidly acting form without the composition of one or the other form changing in the course of storage due to exchange.</p>
    <p>Although the invention in essence relates to rapidly acting insulin derivatives, it accordingly, however, also comprises the possibility of preparing derivatives of this type as a depot form for the purpose of miscibility, the depot auxiliary preferably being protamine sulfate and the insulin derivative and/or its physiologically tolerable salt being present with the protamine sulfate in a cocrystallizate.</p>
    <p>The present invention further relates to an injectable solution which comprises the pharmaceutical preparations described above in dissolved form.</p>
    <heading>EXAMPLES</heading> <heading>Example 1</heading> <p>Construction of Lys (B3)-proinsulin as a Starting Point for the Plasmids Relevant to the Invention Corresponding to Examples 2-4</p>
    <p>U.S. Pat. No. 5,358,857 describes the vector pINT 90d and the PCR primers Tir and Insu 11. These components serve as starting materials for the construction of a plasmid pINT 125d, which codes for the desired Lys (B3)-proinsulin.</p>
    <p>Additionally, the primers Insu 35 having the sequence</p>
    <p>5′ TTT GTG AAG CAG CAC CTG 3′ (SEQ ID NO: 12)</p>
    <p>and Insu 36 having the sequence</p>
    <p>5′ CAG GTG CTG CTT CAC AAA 3′ (SEQ ID NO: 12)</p>
    <p>are synthesized.</p>
    <p>A PCR reaction is carried out using the primers Tir and Insu 36 and a second reaction is carried out using the primers Insu 11 and Insu 35. The template used for this is pINT 90d DNA.</p>
    <p>The products of the two PCR reactions are partially complementary, such that when they are combined in a third PCR reaction with the primers Tir and Insu 11 they afford a fragment which codes for a proinsulin variant which contains the B chain lysine in position 3. This PCR fragment is precipitated in ethanol for purification, dried and then digested with the restriction enzymes Nco 1 and Sal 1 according to the instructions of the manufacturer. The reaction mixture is separated by gel electrophoresis and the desired Nco 1/Sal 1 fragment is isolated.</p>
    <p>The application cited describes a plasmid pINT 91d which codes for a mini-proinsulin. If the sequence coding for mini-proinsulin is excised by means of Nco 1 and Sal 1 and the residual plasmid DNA is isolated, this residual plasmid DNA can be reacted with the shown Nco 1/Sal 1 PCR fragment in a T 4 ligase reaction to give the plasmid pINT 125d. This is transformed by <i>E. coli </i>K12, replicated therein and reisolated. After verification of the plasmid structure by means of DNA sequence and restriction analysis, pINT 125d DNA is used as template DNA for the introduction of further mutations into this proinsulin variant.</p>
    <heading>Example 2</heading> <p>Construction of Lys (B3) Glu (B29)-proinsulin</p>
    <p>For the preparation of the mutein, the primers 329a having the sequence</p>
    <p>5′ TTC TAC ACA CCC GAG ACC CGC GGC ATC G-3′ (SEQ ID NO: 13)</p>
    <p>and 329b having the sequence</p>
    <p>5′ GCC GCG GGT CTC GGG TGT GTA GAA GAA GC 3′ (SEQ ID NO: 14)</p>
    <p>are synthesized.</p>
    <p>The template used is DNA of the plasmids pINT125d and pINT91d. Primer 329a is reacted with the primer Insu 11 on the template pINT91d and primer 329b is reacted with Tir (see above example) on the template pINT125d in a PCR reaction. Since both PCR products are partially complementary, they can be combined in a direct PCR reaction and reacted again with the primers Tir and Insu 11. A DNA fragment results which codes for the desired mutein. This fragment is double-digested using the restriction enzymes Nco 1 and Sal 1 and the resulting Nco 1/Sal 1 fragment is inserted into the pINT 91 d residual plasmid DNA in a T4 ligase reaction.</p>
    <p>The plasmid pINT 329 results, which after amplification in <i>E. coli </i>K12 by means of restriction and DNA sequence analysis is verified with respect to the desired structure.</p>
    <p>The proinsulin derivative encoded by the plasmid is characterized by the two amino acid replacements and a C-bonding member which consists of the amino acid arginine.</p>
    <heading>Example 3</heading> <p>Construction of Lys (B3) Ile (B27)-proinsulin</p>
    <p>The construction is carried out according to the preceding example using the primer pairs</p>
    <p>KB3 JB 27A</p>
    <p>5′ TTC TAC ATC CCC AAG ACC CGC CG 3′ (SEQ ID NO: 15)</p>
    <p>and Insu 11</p>
    <p>and also</p>
    <p>K B3 J 27B</p>
    <p>5′ CTT GGG GAT GTA GAA GAA GCC TCG 3′ (SEQ ID NO: 16)</p>
    <p>and Tir.</p>
    <p>The template used in both PCR reactions is DNA of the plasmid pINT125d. The PCR products of both reactions are combined in a third reaction, as described in Example 1, and the product is cloned corresponding to the example.</p>
    <p>The plasmid pINT332 results.</p>
    <heading>Example 4</heading> <p>Construction of Lys (B3) Ile (B28)-proinsulin</p>
    <p>The construction is carried out according to Example 3 using the primer pairs:</p>
    <p>KB3 JB 28A</p>
    <p>5′ TAC ACA ATC AAG ACC CGC CGG GAG-3′ (SEQ ID NO: 17)</p>
    <p>and Insu 11</p>
    <p>and also</p>
    <p>KB J B28B</p>
    <p>5′ GGT CTT GAT TGT GTA GM GM GCC TCG-3′ (SEQ ID NO: 18)</p>
    <p>and Tir.</p>
    <p>The plasmid pINT 333 results.</p>
    <p>Expression of the constructed insulin variants</p>
    <p>The plasmids pINT 329, 332 and 333 are each transformed by way of example by <i>E. coli </i>K12 W3110. Recombinant bacteria which contain plasmids which encode the respective variants are then fermented according to Example 4 of the US patent having the U.S. Pat. No. 5,227,293 and the desired raw material for the production of the respective insulin variants is thus produced.</p>
    <heading>Example 5</heading> <p>Construction of Lys (B3), Ile (B28), Asp (A21)-proinsulin</p>
    <p>Construction is carried out as in Example 3. instead of pINT125d, however, the template serving for the PCR reaction is DNA of the plasmid pINT333, which was constructed in Example 4. The following primer pair is used here:</p>
    <p>P-pint 365</p>
    <p>5′-TTTTTTGTCGACTATTAGTCGCAGTAGTTCTACCAGCTG-3′ (SEQ ID NO: 19)</p>
    <p>and Tir.</p>
    <p>The plasmid pINT365 results.</p>
    <heading>Example 6</heading> <p>Biological Activity of Lys(B3),Glu(B29)-insulin After Intravenous Administration to Rabbits</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup cols="3" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="70PT"> </colspec> <colspec colname="2" align="center" colwidth="28PT"> </colspec> <colspec colname="3" align="center" colwidth="119PT"> </colspec> <thead valign="bottom"> <tr class="description-tr"> <td namest="1" nameend="3" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td">Human</td>
                <td morerows="0" valign="top" class="description-td">Lys(B3),Glu(B29)-</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">[h]</td>
                <td morerows="0" valign="top" class="description-td">insulin</td>
                <td morerows="0" valign="top" class="description-td">insulin</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="3"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup cols="3" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="char" char="." colwidth="70PT"> </colspec> <colspec colname="2" align="char" char="." colwidth="28PT"> </colspec> <colspec colname="3" align="char" char="." colwidth="119PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">100</td>
                <td morerows="0" valign="top" class="description-td">100</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">0.25</td>
                <td morerows="0" valign="top" class="description-td">89.17</td>
                <td morerows="0" valign="top" class="description-td">89.47</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">0.5</td>
                <td morerows="0" valign="top" class="description-td">67.56</td>
                <td morerows="0" valign="top" class="description-td">58.32</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">0.75</td>
                <td morerows="0" valign="top" class="description-td">73.24</td>
                <td morerows="0" valign="top" class="description-td">66.59</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">1</td>
                <td morerows="0" valign="top" class="description-td">73.13</td>
                <td morerows="0" valign="top" class="description-td">68.21</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">1.5</td>
                <td morerows="0" valign="top" class="description-td">78.12</td>
                <td morerows="0" valign="top" class="description-td">71.95</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">2</td>
                <td morerows="0" valign="top" class="description-td">89.47</td>
                <td morerows="0" valign="top" class="description-td">80.88</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">3</td>
                <td morerows="0" valign="top" class="description-td">107.01</td>
                <td morerows="0" valign="top" class="description-td">94.2</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">4</td>
                <td morerows="0" valign="top" class="description-td">104.55</td>
                <td morerows="0" valign="top" class="description-td">99.78</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>8 rabbits received the indicated insulins intravenously (0.2 IU/kg). In the course of the following four hours, the blood glucose concentration was determined at the times indicated and calculated in % of the starting value at time 0. The mean values show no significant differences in the biological activity between human insulin and Lys(B3),Glu(B29)-insulin.</p>
    <heading>Example 7</heading> <p>Biological Activity of Lys(B3),Ile(B27)- and Lys(B3),Ile(B28)-insulin After Intravenous Administration to Rabbits</p>
    <p>6 rabbits received the indicated insulins intravenously (0.2 IU/kg). In the course of the following four hours, the blood glucose concentration was determined at the times indicated and calculated in % of the starting value at time 0. The mean values show no significant differences in the biological activity between human insulin, Lys(B3),Ile(B27)- and Lys(B3),Ile(B28)-insulin.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup cols="5" colsep="0" rowsep="0" align="left"> <colspec colname="OFFSET" align="left" colwidth="14PT"> </colspec> <colspec colname="1" align="center" colwidth="21PT"> </colspec> <colspec colname="2" align="center" colwidth="49PT"> </colspec> <colspec colname="3" align="center" colwidth="56PT"> </colspec> <colspec colname="4" align="center" colwidth="77PT"> </colspec> <thead valign="bottom"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td namest="OFFSET" nameend="4" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="5"> </td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">Lys(B3),Ile(B27)-</td>
                <td morerows="0" valign="top" class="description-td">Lys(B3),Ile(B28)-</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">[h]</td>
                <td morerows="0" valign="top" class="description-td">H insulin</td>
                <td morerows="0" valign="top" class="description-td">insulin</td>
                <td morerows="0" valign="top" class="description-td">insulin</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td namest="OFFSET" nameend="4" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="5"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup cols="5" colsep="0" rowsep="0" align="left"> <colspec colname="OFFSET" align="left" colwidth="14PT"> </colspec> <colspec colname="1" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="2" align="char" char="." colwidth="49PT"> </colspec> <colspec colname="3" align="char" char="." colwidth="56PT"> </colspec> <colspec colname="4" align="char" char="." colwidth="77PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">100</td>
                <td morerows="0" valign="top" class="description-td">100</td>
                <td morerows="0" valign="top" class="description-td">100</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">0.33</td>
                <td morerows="0" valign="top" class="description-td">67.8</td>
                <td morerows="0" valign="top" class="description-td">62.6</td>
                <td morerows="0" valign="top" class="description-td">63.3</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">0.66</td>
                <td morerows="0" valign="top" class="description-td">54.9</td>
                <td morerows="0" valign="top" class="description-td">60.6</td>
                <td morerows="0" valign="top" class="description-td">55.8</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">1</td>
                <td morerows="0" valign="top" class="description-td">55.2</td>
                <td morerows="0" valign="top" class="description-td">66.8</td>
                <td morerows="0" valign="top" class="description-td">59.3</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">1.5</td>
                <td morerows="0" valign="top" class="description-td">63</td>
                <td morerows="0" valign="top" class="description-td">79.2</td>
                <td morerows="0" valign="top" class="description-td">66.7</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">2</td>
                <td morerows="0" valign="top" class="description-td">77.8</td>
                <td morerows="0" valign="top" class="description-td">90.9</td>
                <td morerows="0" valign="top" class="description-td">81.6</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">3</td>
                <td morerows="0" valign="top" class="description-td">91.5</td>
                <td morerows="0" valign="top" class="description-td">96.3</td>
                <td morerows="0" valign="top" class="description-td">97.2</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">4</td>
                <td morerows="0" valign="top" class="description-td">99.5</td>
                <td morerows="0" valign="top" class="description-td">96</td>
                <td morerows="0" valign="top" class="description-td">101.6</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td namest="OFFSET" nameend="4" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="5"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>Example 8</heading> <p>Pharmacodynamics of Lys(B3),Glu(B29)-insulin and Lys(B3), le(B28)-insulin after Subcutaneous Administration to Dogs</p>
    <p>Four dogs in each case received subcutaneous injections of the indicated insulins (0.3 IU/kg). The blood glucose was kept at 3.7 to 4 mmol/l by continuous infusion of glucose. The mean glucose infusion rate±SEM from the time of injection (t=0) through 240 minutes is shown.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" pgwide="1" class="description-table"> <tgroup cols="1" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="301PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">GLUCOSE CLAMP IN FASTING DOGS WITH RAPIDLY ACTING INSULIN DERIVATIVES</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Characteristics of the glucose infusion profiles</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Dose: 1 × 0.3 IU/kg s.c at t<sub>0    (n = 4)</sub> </td>
              </tr> </tbody> </tgroup> <tgroup cols="4" colsep="0" rowsep="0" align="left"> <colspec colname="OFFSET" align="left" colwidth="84PT"> </colspec> <colspec colname="1" align="center" colwidth="98PT"> </colspec> <colspec colname="2" align="center" colwidth="21PT"> </colspec> <colspec colname="3" align="center" colwidth="98PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">Increment phase</td>
                <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">Decrement phase</td>
              </tr> </tbody> </tgroup> <tgroup cols="6" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="left" colwidth="84PT"> </colspec> <colspec colname="2" align="center" colwidth="49PT"> </colspec> <colspec colname="3" align="center" colwidth="49PT"> </colspec> <colspec colname="4" align="center" colwidth="21PT"> </colspec> <colspec colname="5" align="center" colwidth="49PT"> </colspec> <colspec colname="6" align="center" colwidth="49PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">Inflection point</td>
                <td morerows="0" valign="top" class="description-td">Slope of the</td>
                <td morerows="0" valign="top" class="description-td">t<sub>max</sub> </td>
                <td morerows="0" valign="top" class="description-td">Inflection point</td>
                <td morerows="0" valign="top" class="description-td">Slope of the</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Preparation</td>
                <td morerows="0" valign="top" class="description-td">(min)</td>
                <td morerows="0" valign="top" class="description-td">inflection point</td>
                <td morerows="0" valign="top" class="description-td">(min)</td>
                <td morerows="0" valign="top" class="description-td">(min)</td>
                <td morerows="0" valign="top" class="description-td">inflection point</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="6" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="6"> </td>
              </tr> </tbody> </tgroup> <tgroup cols="6" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="left" colwidth="84PT"> </colspec> <colspec colname="2" align="center" colwidth="49PT"> </colspec> <colspec colname="3" align="center" colwidth="49PT"> </colspec> <colspec colname="4" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="5" align="center" colwidth="49PT"> </colspec> <colspec colname="6" align="center" colwidth="49PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">H. insulin, Hoechst</td>
                <td morerows="0" valign="top" class="description-td">43</td>
                <td morerows="0" valign="top" class="description-td">0.144</td>
                <td morerows="0" valign="top" class="description-td">100</td>
                <td morerows="0" valign="top" class="description-td">156</td>
                <td morerows="0" valign="top" class="description-td">−0.065</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Lys(B3), Glu(B29) insulin</td>
                <td morerows="0" valign="top" class="description-td">33</td>
                <td morerows="0" valign="top" class="description-td">0.227</td>
                <td morerows="0" valign="top" class="description-td">80</td>
                <td morerows="0" valign="top" class="description-td">127</td>
                <td morerows="0" valign="top" class="description-td">−0.091</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Lys(B3), Ile(B28) insulin</td>
                <td morerows="0" valign="top" class="description-td">16</td>
                <td morerows="0" valign="top" class="description-td">0.267</td>
                <td morerows="0" valign="top" class="description-td">60</td>
                <td morerows="0" valign="top" class="description-td">104</td>
                <td morerows="0" valign="top" class="description-td">−0.102</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="6" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="6"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" pgwide="1" class="description-table"> <tgroup cols="1" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="441PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">GLUCOSE CLAMP IN FASTING DOGS WITH RAPIDLY ACTING INSULIN DERIVATIVES</td>
              </tr> </tbody> </tgroup> <tgroup cols="2" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="217PT"> </colspec> <colspec colname="2" align="center" colwidth="224PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Dose: 1 × 0.3 IU/kg s.c. at t<sub>0</sub> </td>
                <td morerows="0" valign="top" class="description-td">(mean ± sem, n = 4)</td>
              </tr> </tbody> </tgroup> <tgroup cols="3" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="147PT"> </colspec> <colspec colname="2" align="center" colwidth="147PT"> </colspec> <colspec colname="3" align="center" colwidth="147PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">H. insulin, Hoechst</td>
                <td morerows="0" valign="top" class="description-td">Lys (B3), Glu (B29) -Insulin</td>
                <td morerows="0" valign="top" class="description-td">Lys (B3), Ile (B28)-Insulin</td>
              </tr> </tbody> </tgroup> <tgroup cols="6" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="77PT"> </colspec> <colspec colname="2" align="center" colwidth="70PT"> </colspec> <colspec colname="3" align="center" colwidth="77PT"> </colspec> <colspec colname="4" align="center" colwidth="70PT"> </colspec> <colspec colname="5" align="center" colwidth="77PT"> </colspec> <colspec colname="6" align="center" colwidth="70PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Glucose infusion rate</td>
                <td morerows="0" valign="top" class="description-td">Blood glucose</td>
                <td morerows="0" valign="top" class="description-td">Glucose infusion rate</td>
                <td morerows="0" valign="top" class="description-td">Blood glucose</td>
                <td morerows="0" valign="top" class="description-td">Glucose infusion rate</td>
                <td morerows="0" valign="top" class="description-td">Blood glucose</td>
              </tr> </tbody> </tgroup> <tgroup cols="12" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="21PT"> </colspec> <colspec colname="2" align="center" colwidth="56PT"> </colspec> <colspec colname="3" align="center" colwidth="21PT"> </colspec> <colspec colname="4" align="center" colwidth="49PT"> </colspec> <colspec colname="5" align="center" colwidth="21PT"> </colspec> <colspec colname="6" align="center" colwidth="56PT"> </colspec> <colspec colname="7" align="center" colwidth="21PT"> </colspec> <colspec colname="8" align="center" colwidth="49PT"> </colspec> <colspec colname="9" align="center" colwidth="21PT"> </colspec> <colspec colname="10" align="center" colwidth="56PT"> </colspec> <colspec colname="11" align="center" colwidth="21PT"> </colspec> <colspec colname="12" align="center" colwidth="49PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td">mg•min<sup>−1</sup>•kg<sup>−1</sup> </td>
                <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td">mmol/l</td>
                <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td">mg•min<sup>−1</sup>•kg<sup>−1</sup> </td>
                <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td">mmol/l</td>
                <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td">mg•min<sup>−1</sup>•kg<sup>−1</sup> </td>
                <td morerows="0" valign="top" class="description-td">Time</td>
                <td morerows="0" valign="top" class="description-td">mmol/l</td>
              </tr> </tbody> </tgroup> <tgroup cols="18" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="center" colwidth="21PT"> </colspec> <colspec colname="2" align="center" colwidth="35PT"> </colspec> <colspec colname="3" align="center" colwidth="21PT"> </colspec> <colspec colname="4" align="center" colwidth="21PT"> </colspec> <colspec colname="5" align="center" colwidth="28PT"> </colspec> <colspec colname="6" align="center" colwidth="21PT"> </colspec> <colspec colname="7" align="center" colwidth="21PT"> </colspec> <colspec colname="8" align="center" colwidth="35PT"> </colspec> <colspec colname="9" align="center" colwidth="21PT"> </colspec> <colspec colname="10" align="center" colwidth="21PT"> </colspec> <colspec colname="11" align="center" colwidth="28PT"> </colspec> <colspec colname="12" align="center" colwidth="21PT"> </colspec> <colspec colname="13" align="center" colwidth="21PT"> </colspec> <colspec colname="14" align="center" colwidth="35PT"> </colspec> <colspec colname="15" align="center" colwidth="21PT"> </colspec> <colspec colname="16" align="center" colwidth="21PT"> </colspec> <colspec colname="17" align="center" colwidth="28PT"> </colspec> <colspec colname="18" align="center" colwidth="21PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">min</td>
                <td morerows="0" valign="top" class="description-td">mean</td>
                <td morerows="0" valign="top" class="description-td">sem</td>
                <td morerows="0" valign="top" class="description-td">min</td>
                <td morerows="0" valign="top" class="description-td">mean</td>
                <td morerows="0" valign="top" class="description-td">sem</td>
                <td morerows="0" valign="top" class="description-td">min</td>
                <td morerows="0" valign="top" class="description-td">mean</td>
                <td morerows="0" valign="top" class="description-td">sem</td>
                <td morerows="0" valign="top" class="description-td">min</td>
                <td morerows="0" valign="top" class="description-td">mean</td>
                <td morerows="0" valign="top" class="description-td">sem</td>
                <td morerows="0" valign="top" class="description-td">min</td>
                <td morerows="0" valign="top" class="description-td">mean</td>
                <td morerows="0" valign="top" class="description-td">sem</td>
                <td morerows="0" valign="top" class="description-td">min</td>
                <td morerows="0" valign="top" class="description-td">mean</td>
                <td morerows="0" valign="top" class="description-td">sem</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="18" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="18"> </td>
              </tr> </tbody> </tgroup> <tgroup cols="18" colsep="0" rowsep="0" align="left"> <colspec colname="1" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="2" align="center" colwidth="35PT"> </colspec> <colspec colname="3" align="center" colwidth="21PT"> </colspec> <colspec colname="4" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="5" align="center" colwidth="28PT"> </colspec> <colspec colname="6" align="center" colwidth="21PT"> </colspec> <colspec colname="7" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="8" align="char" char="." colwidth="35PT"> </colspec> <colspec colname="9" align="center" colwidth="21PT"> </colspec> <colspec colname="10" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="11" align="center" colwidth="28PT"> </colspec> <colspec colname="12" align="center" colwidth="21PT"> </colspec> <colspec colname="13" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="14" align="char" char="." colwidth="35PT"> </colspec> <colspec colname="15" align="center" colwidth="21PT"> </colspec> <colspec colname="16" align="char" char="." colwidth="21PT"> </colspec> <colspec colname="17" align="center" colwidth="28PT"> </colspec> <colspec colname="18" align="center" colwidth="21PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">3.98</td>
                <td morerows="0" valign="top" class="description-td">0.07</td>
                <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">3.77</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">0</td>
                <td morerows="0" valign="top" class="description-td">3.74</td>
                <td morerows="0" valign="top" class="description-td">0.07</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">6</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">0.01</td>
                <td morerows="0" valign="top" class="description-td">4</td>
                <td morerows="0" valign="top" class="description-td">3.97</td>
                <td morerows="0" valign="top" class="description-td">0.04</td>
                <td morerows="0" valign="top" class="description-td">6</td>
                <td morerows="0" valign="top" class="description-td">0.24</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">5</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.22</td>
                <td morerows="0" valign="top" class="description-td">6</td>
                <td morerows="0" valign="top" class="description-td">1.54</td>
                <td morerows="0" valign="top" class="description-td">0.53</td>
                <td morerows="0" valign="top" class="description-td">4</td>
                <td morerows="0" valign="top" class="description-td">3.60</td>
                <td morerows="0" valign="top" class="description-td">0.17</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">11</td>
                <td morerows="0" valign="top" class="description-td">0.23</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">9</td>
                <td morerows="0" valign="top" class="description-td">3.98</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">11</td>
                <td morerows="0" valign="top" class="description-td">0.36</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
                <td morerows="0" valign="top" class="description-td">10</td>
                <td morerows="0" valign="top" class="description-td">3.86</td>
                <td morerows="0" valign="top" class="description-td">0.17</td>
                <td morerows="0" valign="top" class="description-td">11</td>
                <td morerows="0" valign="top" class="description-td">3.75</td>
                <td morerows="0" valign="top" class="description-td">1.24</td>
                <td morerows="0" valign="top" class="description-td">10</td>
                <td morerows="0" valign="top" class="description-td">3.49</td>
                <td morerows="0" valign="top" class="description-td">0.19</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">16</td>
                <td morerows="0" valign="top" class="description-td">0.35</td>
                <td morerows="0" valign="top" class="description-td">0.19</td>
                <td morerows="0" valign="top" class="description-td">14</td>
                <td morerows="0" valign="top" class="description-td">3.99</td>
                <td morerows="0" valign="top" class="description-td">0.04</td>
                <td morerows="0" valign="top" class="description-td">16</td>
                <td morerows="0" valign="top" class="description-td">0.95</td>
                <td morerows="0" valign="top" class="description-td">0.60</td>
                <td morerows="0" valign="top" class="description-td">15</td>
                <td morerows="0" valign="top" class="description-td">3.86</td>
                <td morerows="0" valign="top" class="description-td">0.22</td>
                <td morerows="0" valign="top" class="description-td">16</td>
                <td morerows="0" valign="top" class="description-td">5.25</td>
                <td morerows="0" valign="top" class="description-td">0.89</td>
                <td morerows="0" valign="top" class="description-td">15</td>
                <td morerows="0" valign="top" class="description-td">3.53</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">21</td>
                <td morerows="0" valign="top" class="description-td">0.44</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
                <td morerows="0" valign="top" class="description-td">19</td>
                <td morerows="0" valign="top" class="description-td">4.01</td>
                <td morerows="0" valign="top" class="description-td">0.05</td>
                <td morerows="0" valign="top" class="description-td">21</td>
                <td morerows="0" valign="top" class="description-td">2.75</td>
                <td morerows="0" valign="top" class="description-td">0.96</td>
                <td morerows="0" valign="top" class="description-td">20</td>
                <td morerows="0" valign="top" class="description-td">3.61</td>
                <td morerows="0" valign="top" class="description-td">0.16</td>
                <td morerows="0" valign="top" class="description-td">21</td>
                <td morerows="0" valign="top" class="description-td">8.25</td>
                <td morerows="0" valign="top" class="description-td">1.67</td>
                <td morerows="0" valign="top" class="description-td">20</td>
                <td morerows="0" valign="top" class="description-td">3.38</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">26</td>
                <td morerows="0" valign="top" class="description-td">1.50</td>
                <td morerows="0" valign="top" class="description-td">0.25</td>
                <td morerows="0" valign="top" class="description-td">24</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">26</td>
                <td morerows="0" valign="top" class="description-td">3.25</td>
                <td morerows="0" valign="top" class="description-td">0.65</td>
                <td morerows="0" valign="top" class="description-td">25</td>
                <td morerows="0" valign="top" class="description-td">3.73</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">26</td>
                <td morerows="0" valign="top" class="description-td">7.25</td>
                <td morerows="0" valign="top" class="description-td">1.63</td>
                <td morerows="0" valign="top" class="description-td">25</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.20</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">31</td>
                <td morerows="0" valign="top" class="description-td">3.50</td>
                <td morerows="0" valign="top" class="description-td">0.56</td>
                <td morerows="0" valign="top" class="description-td">29</td>
                <td morerows="0" valign="top" class="description-td">3.82</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
                <td morerows="0" valign="top" class="description-td">31</td>
                <td morerows="0" valign="top" class="description-td">3.75</td>
                <td morerows="0" valign="top" class="description-td">0.22</td>
                <td morerows="0" valign="top" class="description-td">30</td>
                <td morerows="0" valign="top" class="description-td">3.76</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">31</td>
                <td morerows="0" valign="top" class="description-td">7.50</td>
                <td morerows="0" valign="top" class="description-td">1.25</td>
                <td morerows="0" valign="top" class="description-td">30</td>
                <td morerows="0" valign="top" class="description-td">3.64</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">36</td>
                <td morerows="0" valign="top" class="description-td">5.50</td>
                <td morerows="0" valign="top" class="description-td">0.90</td>
                <td morerows="0" valign="top" class="description-td">34</td>
                <td morerows="0" valign="top" class="description-td">3.77</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
                <td morerows="0" valign="top" class="description-td">36</td>
                <td morerows="0" valign="top" class="description-td">5.25</td>
                <td morerows="0" valign="top" class="description-td">0.41</td>
                <td morerows="0" valign="top" class="description-td">35</td>
                <td morerows="0" valign="top" class="description-td">3.66</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
                <td morerows="0" valign="top" class="description-td">36</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">1.15</td>
                <td morerows="0" valign="top" class="description-td">35</td>
                <td morerows="0" valign="top" class="description-td">3.65</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">41</td>
                <td morerows="0" valign="top" class="description-td">4.50</td>
                <td morerows="0" valign="top" class="description-td">0.56</td>
                <td morerows="0" valign="top" class="description-td">39</td>
                <td morerows="0" valign="top" class="description-td">3.99</td>
                <td morerows="0" valign="top" class="description-td">0.07</td>
                <td morerows="0" valign="top" class="description-td">41</td>
                <td morerows="0" valign="top" class="description-td">6.00</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">40</td>
                <td morerows="0" valign="top" class="description-td">3.71</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">41</td>
                <td morerows="0" valign="top" class="description-td">11.00</td>
                <td morerows="0" valign="top" class="description-td">1.12</td>
                <td morerows="0" valign="top" class="description-td">40</td>
                <td morerows="0" valign="top" class="description-td">3.63</td>
                <td morerows="0" valign="top" class="description-td">0.09</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">46</td>
                <td morerows="0" valign="top" class="description-td">4.00</td>
                <td morerows="0" valign="top" class="description-td">1.17</td>
                <td morerows="0" valign="top" class="description-td">44</td>
                <td morerows="0" valign="top" class="description-td">4.09</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
                <td morerows="0" valign="top" class="description-td">46</td>
                <td morerows="0" valign="top" class="description-td">9.00</td>
                <td morerows="0" valign="top" class="description-td">0.87</td>
                <td morerows="0" valign="top" class="description-td">45</td>
                <td morerows="0" valign="top" class="description-td">3.58</td>
                <td morerows="0" valign="top" class="description-td">0.19</td>
                <td morerows="0" valign="top" class="description-td">46</td>
                <td morerows="0" valign="top" class="description-td">11.75</td>
                <td morerows="0" valign="top" class="description-td">0.22</td>
                <td morerows="0" valign="top" class="description-td">45</td>
                <td morerows="0" valign="top" class="description-td">3.68</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">51</td>
                <td morerows="0" valign="top" class="description-td">5.25</td>
                <td morerows="0" valign="top" class="description-td">0.54</td>
                <td morerows="0" valign="top" class="description-td">49</td>
                <td morerows="0" valign="top" class="description-td">3.98</td>
                <td morerows="0" valign="top" class="description-td">0.06</td>
                <td morerows="0" valign="top" class="description-td">51</td>
                <td morerows="0" valign="top" class="description-td">8.00</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">50</td>
                <td morerows="0" valign="top" class="description-td">3.73</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">51</td>
                <td morerows="0" valign="top" class="description-td">10.75</td>
                <td morerows="0" valign="top" class="description-td">0.96</td>
                <td morerows="0" valign="top" class="description-td">50</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.09</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">56</td>
                <td morerows="0" valign="top" class="description-td">5.75</td>
                <td morerows="0" valign="top" class="description-td">0.89</td>
                <td morerows="0" valign="top" class="description-td">54</td>
                <td morerows="0" valign="top" class="description-td">4.01</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
                <td morerows="0" valign="top" class="description-td">56</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">0.56</td>
                <td morerows="0" valign="top" class="description-td">55</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
                <td morerows="0" valign="top" class="description-td">56</td>
                <td morerows="0" valign="top" class="description-td">11.25</td>
                <td morerows="0" valign="top" class="description-td">1.78</td>
                <td morerows="0" valign="top" class="description-td">55</td>
                <td morerows="0" valign="top" class="description-td">3.73</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">61</td>
                <td morerows="0" valign="top" class="description-td">7.25</td>
                <td morerows="0" valign="top" class="description-td">1.19</td>
                <td morerows="0" valign="top" class="description-td">59</td>
                <td morerows="0" valign="top" class="description-td">3.93</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
                <td morerows="0" valign="top" class="description-td">61</td>
                <td morerows="0" valign="top" class="description-td">11.50</td>
                <td morerows="0" valign="top" class="description-td">0.43</td>
                <td morerows="0" valign="top" class="description-td">60</td>
                <td morerows="0" valign="top" class="description-td">3.57</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">61</td>
                <td morerows="0" valign="top" class="description-td">10.50</td>
                <td morerows="0" valign="top" class="description-td">1.09</td>
                <td morerows="0" valign="top" class="description-td">60</td>
                <td morerows="0" valign="top" class="description-td">3.78</td>
                <td morerows="0" valign="top" class="description-td">0.16</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">66</td>
                <td morerows="0" valign="top" class="description-td">6.50</td>
                <td morerows="0" valign="top" class="description-td">1.09</td>
                <td morerows="0" valign="top" class="description-td">64</td>
                <td morerows="0" valign="top" class="description-td">4.08</td>
                <td morerows="0" valign="top" class="description-td">0.06</td>
                <td morerows="0" valign="top" class="description-td">67</td>
                <td morerows="0" valign="top" class="description-td">10.00</td>
                <td morerows="0" valign="top" class="description-td">1.22</td>
                <td morerows="0" valign="top" class="description-td">65</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.20</td>
                <td morerows="0" valign="top" class="description-td">66</td>
                <td morerows="0" valign="top" class="description-td">9.75</td>
                <td morerows="0" valign="top" class="description-td">1.85</td>
                <td morerows="0" valign="top" class="description-td">65</td>
                <td morerows="0" valign="top" class="description-td">3.83</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">71</td>
                <td morerows="0" valign="top" class="description-td">7.75</td>
                <td morerows="0" valign="top" class="description-td">1.08</td>
                <td morerows="0" valign="top" class="description-td">69</td>
                <td morerows="0" valign="top" class="description-td">3.98</td>
                <td morerows="0" valign="top" class="description-td">0.01</td>
                <td morerows="0" valign="top" class="description-td">71</td>
                <td morerows="0" valign="top" class="description-td">11.50</td>
                <td morerows="0" valign="top" class="description-td">0.43</td>
                <td morerows="0" valign="top" class="description-td">70</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.23</td>
                <td morerows="0" valign="top" class="description-td">71</td>
                <td morerows="0" valign="top" class="description-td">11.00</td>
                <td morerows="0" valign="top" class="description-td">1.50</td>
                <td morerows="0" valign="top" class="description-td">70</td>
                <td morerows="0" valign="top" class="description-td">3.69</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">76</td>
                <td morerows="0" valign="top" class="description-td">7.75</td>
                <td morerows="0" valign="top" class="description-td">1.14</td>
                <td morerows="0" valign="top" class="description-td">74</td>
                <td morerows="0" valign="top" class="description-td">4.08</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
                <td morerows="0" valign="top" class="description-td">76</td>
                <td morerows="0" valign="top" class="description-td">11.00</td>
                <td morerows="0" valign="top" class="description-td">1.70</td>
                <td morerows="0" valign="top" class="description-td">75</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.28</td>
                <td morerows="0" valign="top" class="description-td">76</td>
                <td morerows="0" valign="top" class="description-td">10.50</td>
                <td morerows="0" valign="top" class="description-td">0.83</td>
                <td morerows="0" valign="top" class="description-td">75</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.06</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">81</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">1.09</td>
                <td morerows="0" valign="top" class="description-td">79</td>
                <td morerows="0" valign="top" class="description-td">4.03</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">81</td>
                <td morerows="0" valign="top" class="description-td">10.50</td>
                <td morerows="0" valign="top" class="description-td">0.83</td>
                <td morerows="0" valign="top" class="description-td">80</td>
                <td morerows="0" valign="top" class="description-td">3.94</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
                <td morerows="0" valign="top" class="description-td">81</td>
                <td morerows="0" valign="top" class="description-td">9.25</td>
                <td morerows="0" valign="top" class="description-td">1.19</td>
                <td morerows="0" valign="top" class="description-td">80</td>
                <td morerows="0" valign="top" class="description-td">3.89</td>
                <td morerows="0" valign="top" class="description-td">0.01</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">86</td>
                <td morerows="0" valign="top" class="description-td">8.75</td>
                <td morerows="0" valign="top" class="description-td">1.29</td>
                <td morerows="0" valign="top" class="description-td">84</td>
                <td morerows="0" valign="top" class="description-td">4.09</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
                <td morerows="0" valign="top" class="description-td">86</td>
                <td morerows="0" valign="top" class="description-td">8.25</td>
                <td morerows="0" valign="top" class="description-td">1.75</td>
                <td morerows="0" valign="top" class="description-td">85</td>
                <td morerows="0" valign="top" class="description-td">3.95</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
                <td morerows="0" valign="top" class="description-td">86</td>
                <td morerows="0" valign="top" class="description-td">10.00</td>
                <td morerows="0" valign="top" class="description-td">1.22</td>
                <td morerows="0" valign="top" class="description-td">85</td>
                <td morerows="0" valign="top" class="description-td">3.78</td>
                <td morerows="0" valign="top" class="description-td">0.02</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">91</td>
                <td morerows="0" valign="top" class="description-td">8.75</td>
                <td morerows="0" valign="top" class="description-td">1.08</td>
                <td morerows="0" valign="top" class="description-td">89</td>
                <td morerows="0" valign="top" class="description-td">4.03</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
                <td morerows="0" valign="top" class="description-td">91</td>
                <td morerows="0" valign="top" class="description-td">9.00</td>
                <td morerows="0" valign="top" class="description-td">0.50</td>
                <td morerows="0" valign="top" class="description-td">90</td>
                <td morerows="0" valign="top" class="description-td">3.69</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">91</td>
                <td morerows="0" valign="top" class="description-td">8.75</td>
                <td morerows="0" valign="top" class="description-td">1.29</td>
                <td morerows="0" valign="top" class="description-td">90</td>
                <td morerows="0" valign="top" class="description-td">3.83</td>
                <td morerows="0" valign="top" class="description-td">0.04</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">96</td>
                <td morerows="0" valign="top" class="description-td">9.25</td>
                <td morerows="0" valign="top" class="description-td">2.33</td>
                <td morerows="0" valign="top" class="description-td">94</td>
                <td morerows="0" valign="top" class="description-td">3.99</td>
                <td morerows="0" valign="top" class="description-td">0.22</td>
                <td morerows="0" valign="top" class="description-td">96</td>
                <td morerows="0" valign="top" class="description-td">11.00</td>
                <td morerows="0" valign="top" class="description-td">0.94</td>
                <td morerows="0" valign="top" class="description-td">95</td>
                <td morerows="0" valign="top" class="description-td">3.56</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">96</td>
                <td morerows="0" valign="top" class="description-td">10.25</td>
                <td morerows="0" valign="top" class="description-td">0.74</td>
                <td morerows="0" valign="top" class="description-td">95</td>
                <td morerows="0" valign="top" class="description-td">3.67</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">101</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">1.68</td>
                <td morerows="0" valign="top" class="description-td">99</td>
                <td morerows="0" valign="top" class="description-td">4.08</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
                <td morerows="0" valign="top" class="description-td">101</td>
                <td morerows="0" valign="top" class="description-td">9.75</td>
                <td morerows="0" valign="top" class="description-td">0.41</td>
                <td morerows="0" valign="top" class="description-td">100</td>
                <td morerows="0" valign="top" class="description-td">3.71</td>
                <td morerows="0" valign="top" class="description-td">0.16</td>
                <td morerows="0" valign="top" class="description-td">101</td>
                <td morerows="0" valign="top" class="description-td">10.00</td>
                <td morerows="0" valign="top" class="description-td">1.22</td>
                <td morerows="0" valign="top" class="description-td">100</td>
                <td morerows="0" valign="top" class="description-td">3.66</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">106</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">1.44</td>
                <td morerows="0" valign="top" class="description-td">104</td>
                <td morerows="0" valign="top" class="description-td">3.96</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">106</td>
                <td morerows="0" valign="top" class="description-td">10.25</td>
                <td morerows="0" valign="top" class="description-td">0.89</td>
                <td morerows="0" valign="top" class="description-td">105</td>
                <td morerows="0" valign="top" class="description-td">3.59</td>
                <td morerows="0" valign="top" class="description-td">0.20</td>
                <td morerows="0" valign="top" class="description-td">106</td>
                <td morerows="0" valign="top" class="description-td">10.50</td>
                <td morerows="0" valign="top" class="description-td">1.15</td>
                <td morerows="0" valign="top" class="description-td">105</td>
                <td morerows="0" valign="top" class="description-td">3.59</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">111</td>
                <td morerows="0" valign="top" class="description-td">8.00</td>
                <td morerows="0" valign="top" class="description-td">1.06</td>
                <td morerows="0" valign="top" class="description-td">109</td>
                <td morerows="0" valign="top" class="description-td">3.92</td>
                <td morerows="0" valign="top" class="description-td">0.19</td>
                <td morerows="0" valign="top" class="description-td">111</td>
                <td morerows="0" valign="top" class="description-td">8.00</td>
                <td morerows="0" valign="top" class="description-td">0.94</td>
                <td morerows="0" valign="top" class="description-td">110</td>
                <td morerows="0" valign="top" class="description-td">3.84</td>
                <td morerows="0" valign="top" class="description-td">0.16</td>
                <td morerows="0" valign="top" class="description-td">111</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">1.03</td>
                <td morerows="0" valign="top" class="description-td">109</td>
                <td morerows="0" valign="top" class="description-td">3.74</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">116</td>
                <td morerows="0" valign="top" class="description-td">9.25</td>
                <td morerows="0" valign="top" class="description-td">1.47</td>
                <td morerows="0" valign="top" class="description-td">114</td>
                <td morerows="0" valign="top" class="description-td">3.83</td>
                <td morerows="0" valign="top" class="description-td">0.17</td>
                <td morerows="0" valign="top" class="description-td">116</td>
                <td morerows="0" valign="top" class="description-td">10.25</td>
                <td morerows="0" valign="top" class="description-td">0.74</td>
                <td morerows="0" valign="top" class="description-td">115</td>
                <td morerows="0" valign="top" class="description-td">3.40</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
                <td morerows="0" valign="top" class="description-td">116</td>
                <td morerows="0" valign="top" class="description-td">7.75</td>
                <td morerows="0" valign="top" class="description-td">0.22</td>
                <td morerows="0" valign="top" class="description-td">115</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">121</td>
                <td morerows="0" valign="top" class="description-td">8.00</td>
                <td morerows="0" valign="top" class="description-td">1.58</td>
                <td morerows="0" valign="top" class="description-td">119</td>
                <td morerows="0" valign="top" class="description-td">4.04</td>
                <td morerows="0" valign="top" class="description-td">0.21</td>
                <td morerows="0" valign="top" class="description-td">121</td>
                <td morerows="0" valign="top" class="description-td">10.25</td>
                <td morerows="0" valign="top" class="description-td">1.24</td>
                <td morerows="0" valign="top" class="description-td">120</td>
                <td morerows="0" valign="top" class="description-td">3.58</td>
                <td morerows="0" valign="top" class="description-td">0.25</td>
                <td morerows="0" valign="top" class="description-td">121</td>
                <td morerows="0" valign="top" class="description-td">7.50</td>
                <td morerows="0" valign="top" class="description-td">1.09</td>
                <td morerows="0" valign="top" class="description-td">120</td>
                <td morerows="0" valign="top" class="description-td">3.83</td>
                <td morerows="0" valign="top" class="description-td">0.07</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">126</td>
                <td morerows="0" valign="top" class="description-td">8.00</td>
                <td morerows="0" valign="top" class="description-td">1.37</td>
                <td morerows="0" valign="top" class="description-td">124</td>
                <td morerows="0" valign="top" class="description-td">3.95</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">126</td>
                <td morerows="0" valign="top" class="description-td">9.75</td>
                <td morerows="0" valign="top" class="description-td">1.34</td>
                <td morerows="0" valign="top" class="description-td">125</td>
                <td morerows="0" valign="top" class="description-td">3.70</td>
                <td morerows="0" valign="top" class="description-td">0.23</td>
                <td morerows="0" valign="top" class="description-td">126</td>
                <td morerows="0" valign="top" class="description-td">6.00</td>
                <td morerows="0" valign="top" class="description-td">1.62</td>
                <td morerows="0" valign="top" class="description-td">125</td>
                <td morerows="0" valign="top" class="description-td">3.94</td>
                <td morerows="0" valign="top" class="description-td">0.07</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">131</td>
                <td morerows="0" valign="top" class="description-td">9.25</td>
                <td morerows="0" valign="top" class="description-td">1.19</td>
                <td morerows="0" valign="top" class="description-td">129</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.09</td>
                <td morerows="0" valign="top" class="description-td">131</td>
                <td morerows="0" valign="top" class="description-td">7.75</td>
                <td morerows="0" valign="top" class="description-td">1.52</td>
                <td morerows="0" valign="top" class="description-td">130</td>
                <td morerows="0" valign="top" class="description-td">3.88</td>
                <td morerows="0" valign="top" class="description-td">0.21</td>
                <td morerows="0" valign="top" class="description-td">131</td>
                <td morerows="0" valign="top" class="description-td">4.25</td>
                <td morerows="0" valign="top" class="description-td">1.29</td>
                <td morerows="0" valign="top" class="description-td">130</td>
                <td morerows="0" valign="top" class="description-td">3.95</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">136</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">1.30</td>
                <td morerows="0" valign="top" class="description-td">134</td>
                <td morerows="0" valign="top" class="description-td">3.92</td>
                <td morerows="0" valign="top" class="description-td">0.16</td>
                <td morerows="0" valign="top" class="description-td">136</td>
                <td morerows="0" valign="top" class="description-td">5.50</td>
                <td morerows="0" valign="top" class="description-td">1.44</td>
                <td morerows="0" valign="top" class="description-td">135</td>
                <td morerows="0" valign="top" class="description-td">3.97</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
                <td morerows="0" valign="top" class="description-td">136</td>
                <td morerows="0" valign="top" class="description-td">5.33</td>
                <td morerows="0" valign="top" class="description-td">1.19</td>
                <td morerows="0" valign="top" class="description-td">135</td>
                <td morerows="0" valign="top" class="description-td">3.70</td>
                <td morerows="0" valign="top" class="description-td">0.20</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">141</td>
                <td morerows="0" valign="top" class="description-td">8.50</td>
                <td morerows="0" valign="top" class="description-td">1.25</td>
                <td morerows="0" valign="top" class="description-td">139</td>
                <td morerows="0" valign="top" class="description-td">3.86</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
                <td morerows="0" valign="top" class="description-td">141</td>
                <td morerows="0" valign="top" class="description-td">6.75</td>
                <td morerows="0" valign="top" class="description-td">1.85</td>
                <td morerows="0" valign="top" class="description-td">140</td>
                <td morerows="0" valign="top" class="description-td">3.64</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
                <td morerows="0" valign="top" class="description-td">142</td>
                <td morerows="0" valign="top" class="description-td">4.75</td>
                <td morerows="0" valign="top" class="description-td">1.19</td>
                <td morerows="0" valign="top" class="description-td">140</td>
                <td morerows="0" valign="top" class="description-td">3.71</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">146</td>
                <td morerows="0" valign="top" class="description-td">8.25</td>
                <td morerows="0" valign="top" class="description-td">1.24</td>
                <td morerows="0" valign="top" class="description-td">144</td>
                <td morerows="0" valign="top" class="description-td">3.91</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">146</td>
                <td morerows="0" valign="top" class="description-td">6.25</td>
                <td morerows="0" valign="top" class="description-td">1.67</td>
                <td morerows="0" valign="top" class="description-td">145</td>
                <td morerows="0" valign="top" class="description-td">3.71</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">146</td>
                <td morerows="0" valign="top" class="description-td">4.00</td>
                <td morerows="0" valign="top" class="description-td">0.94</td>
                <td morerows="0" valign="top" class="description-td">145</td>
                <td morerows="0" valign="top" class="description-td">3.73</td>
                <td morerows="0" valign="top" class="description-td">0.07</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">151</td>
                <td morerows="0" valign="top" class="description-td">7.00</td>
                <td morerows="0" valign="top" class="description-td">1.46</td>
                <td morerows="0" valign="top" class="description-td">149</td>
                <td morerows="0" valign="top" class="description-td">4.06</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">151</td>
                <td morerows="0" valign="top" class="description-td">4.75</td>
                <td morerows="0" valign="top" class="description-td">1.14</td>
                <td morerows="0" valign="top" class="description-td">150</td>
                <td morerows="0" valign="top" class="description-td">3.82</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">151</td>
                <td morerows="0" valign="top" class="description-td">3.25</td>
                <td morerows="0" valign="top" class="description-td">0.89</td>
                <td morerows="0" valign="top" class="description-td">150</td>
                <td morerows="0" valign="top" class="description-td">3.74</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">156</td>
                <td morerows="0" valign="top" class="description-td">6.25</td>
                <td morerows="0" valign="top" class="description-td">1.29</td>
                <td morerows="0" valign="top" class="description-td">154</td>
                <td morerows="0" valign="top" class="description-td">4.05</td>
                <td morerows="0" valign="top" class="description-td">0.04</td>
                <td morerows="0" valign="top" class="description-td">156</td>
                <td morerows="0" valign="top" class="description-td">5.75</td>
                <td morerows="0" valign="top" class="description-td">0.96</td>
                <td morerows="0" valign="top" class="description-td">155</td>
                <td morerows="0" valign="top" class="description-td">3.71</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
                <td morerows="0" valign="top" class="description-td">156</td>
                <td morerows="0" valign="top" class="description-td">4.00</td>
                <td morerows="0" valign="top" class="description-td">0.71</td>
                <td morerows="0" valign="top" class="description-td">155</td>
                <td morerows="0" valign="top" class="description-td">3.62</td>
                <td morerows="0" valign="top" class="description-td">0.05</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">161</td>
                <td morerows="0" valign="top" class="description-td">6.00</td>
                <td morerows="0" valign="top" class="description-td">0.79</td>
                <td morerows="0" valign="top" class="description-td">159</td>
                <td morerows="0" valign="top" class="description-td">3.97</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">161</td>
                <td morerows="0" valign="top" class="description-td">4.75</td>
                <td morerows="0" valign="top" class="description-td">0.82</td>
                <td morerows="0" valign="top" class="description-td">160</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
                <td morerows="0" valign="top" class="description-td">162</td>
                <td morerows="0" valign="top" class="description-td">3.75</td>
                <td morerows="0" valign="top" class="description-td">0.54</td>
                <td morerows="0" valign="top" class="description-td">160</td>
                <td morerows="0" valign="top" class="description-td">3.69</td>
                <td morerows="0" valign="top" class="description-td">0.09</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">166</td>
                <td morerows="0" valign="top" class="description-td">5.00</td>
                <td morerows="0" valign="top" class="description-td">0.50</td>
                <td morerows="0" valign="top" class="description-td">164</td>
                <td morerows="0" valign="top" class="description-td">4.04</td>
                <td morerows="0" valign="top" class="description-td">0.09</td>
                <td morerows="0" valign="top" class="description-td">166</td>
                <td morerows="0" valign="top" class="description-td">5.50</td>
                <td morerows="0" valign="top" class="description-td">1.03</td>
                <td morerows="0" valign="top" class="description-td">165</td>
                <td morerows="0" valign="top" class="description-td">3.67</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
                <td morerows="0" valign="top" class="description-td">166</td>
                <td morerows="0" valign="top" class="description-td">2.25</td>
                <td morerows="0" valign="top" class="description-td">0.54</td>
                <td morerows="0" valign="top" class="description-td">165</td>
                <td morerows="0" valign="top" class="description-td">3.80</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">171</td>
                <td morerows="0" valign="top" class="description-td">4.75</td>
                <td morerows="0" valign="top" class="description-td">1.39</td>
                <td morerows="0" valign="top" class="description-td">169</td>
                <td morerows="0" valign="top" class="description-td">3.95</td>
                <td morerows="0" valign="top" class="description-td">0.15</td>
                <td morerows="0" valign="top" class="description-td">171</td>
                <td morerows="0" valign="top" class="description-td">4.75</td>
                <td morerows="0" valign="top" class="description-td">0.41</td>
                <td morerows="0" valign="top" class="description-td">169</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.04</td>
                <td morerows="0" valign="top" class="description-td">171</td>
                <td morerows="0" valign="top" class="description-td">2.25</td>
                <td morerows="0" valign="top" class="description-td">0.41</td>
                <td morerows="0" valign="top" class="description-td">170</td>
                <td morerows="0" valign="top" class="description-td">3.75</td>
                <td morerows="0" valign="top" class="description-td">0.05</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">176</td>
                <td morerows="0" valign="top" class="description-td">4.33</td>
                <td morerows="0" valign="top" class="description-td">0.54</td>
                <td morerows="0" valign="top" class="description-td">174</td>
                <td morerows="0" valign="top" class="description-td">4.01</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">176</td>
                <td morerows="0" valign="top" class="description-td">3.75</td>
                <td morerows="0" valign="top" class="description-td">0.54</td>
                <td morerows="0" valign="top" class="description-td">175</td>
                <td morerows="0" valign="top" class="description-td">3.83</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">176</td>
                <td morerows="0" valign="top" class="description-td">1.63</td>
                <td morerows="0" valign="top" class="description-td">0.48</td>
                <td morerows="0" valign="top" class="description-td">175</td>
                <td morerows="0" valign="top" class="description-td">3.77</td>
                <td morerows="0" valign="top" class="description-td">0.05</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">181</td>
                <td morerows="0" valign="top" class="description-td">5.33</td>
                <td morerows="0" valign="top" class="description-td">1.19</td>
                <td morerows="0" valign="top" class="description-td">179</td>
                <td morerows="0" valign="top" class="description-td">3.88</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">181</td>
                <td morerows="0" valign="top" class="description-td">4.00</td>
                <td morerows="0" valign="top" class="description-td">0.94</td>
                <td morerows="0" valign="top" class="description-td">180</td>
                <td morerows="0" valign="top" class="description-td">3.75</td>
                <td morerows="0" valign="top" class="description-td">0.16</td>
                <td morerows="0" valign="top" class="description-td">181</td>
                <td morerows="0" valign="top" class="description-td">1.54</td>
                <td morerows="0" valign="top" class="description-td">0.53</td>
                <td morerows="0" valign="top" class="description-td">180</td>
                <td morerows="0" valign="top" class="description-td">3.77</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">186</td>
                <td morerows="0" valign="top" class="description-td">4.67</td>
                <td morerows="0" valign="top" class="description-td">0.72</td>
                <td morerows="0" valign="top" class="description-td">184</td>
                <td morerows="0" valign="top" class="description-td">4.03</td>
                <td morerows="0" valign="top" class="description-td">0.09</td>
                <td morerows="0" valign="top" class="description-td">186</td>
                <td morerows="0" valign="top" class="description-td">2.88</td>
                <td morerows="0" valign="top" class="description-td">0.87</td>
                <td morerows="0" valign="top" class="description-td">185</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">186</td>
                <td morerows="0" valign="top" class="description-td">0.88</td>
                <td morerows="0" valign="top" class="description-td">0.46</td>
                <td morerows="0" valign="top" class="description-td">185</td>
                <td morerows="0" valign="top" class="description-td">3.76</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">191</td>
                <td morerows="0" valign="top" class="description-td">3.33</td>
                <td morerows="0" valign="top" class="description-td">0.72</td>
                <td morerows="0" valign="top" class="description-td">189</td>
                <td morerows="0" valign="top" class="description-td">4.12</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
                <td morerows="0" valign="top" class="description-td">191</td>
                <td morerows="0" valign="top" class="description-td">3.25</td>
                <td morerows="0" valign="top" class="description-td">0.41</td>
                <td morerows="0" valign="top" class="description-td">190</td>
                <td morerows="0" valign="top" class="description-td">3.78</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
                <td morerows="0" valign="top" class="description-td">191</td>
                <td morerows="0" valign="top" class="description-td">1.19</td>
                <td morerows="0" valign="top" class="description-td">0.54</td>
                <td morerows="0" valign="top" class="description-td">190</td>
                <td morerows="0" valign="top" class="description-td">3.76</td>
                <td morerows="0" valign="top" class="description-td">0.04</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">196</td>
                <td morerows="0" valign="top" class="description-td">3.00</td>
                <td morerows="0" valign="top" class="description-td">0.00</td>
                <td morerows="0" valign="top" class="description-td">194</td>
                <td morerows="0" valign="top" class="description-td">4.13</td>
                <td morerows="0" valign="top" class="description-td">0.03</td>
                <td morerows="0" valign="top" class="description-td">196</td>
                <td morerows="0" valign="top" class="description-td">3.13</td>
                <td morerows="0" valign="top" class="description-td">0.84</td>
                <td morerows="0" valign="top" class="description-td">195</td>
                <td morerows="0" valign="top" class="description-td">3.81</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">196</td>
                <td morerows="0" valign="top" class="description-td">1.28</td>
                <td morerows="0" valign="top" class="description-td">0.79</td>
                <td morerows="0" valign="top" class="description-td">195</td>
                <td morerows="0" valign="top" class="description-td">3.76</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">201</td>
                <td morerows="0" valign="top" class="description-td">3.67</td>
                <td morerows="0" valign="top" class="description-td">0.72</td>
                <td morerows="0" valign="top" class="description-td">199</td>
                <td morerows="0" valign="top" class="description-td">3.98</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
                <td morerows="0" valign="top" class="description-td">201</td>
                <td morerows="0" valign="top" class="description-td">2.13</td>
                <td morerows="0" valign="top" class="description-td">0.51</td>
                <td morerows="0" valign="top" class="description-td">200</td>
                <td morerows="0" valign="top" class="description-td">3.88</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
                <td morerows="0" valign="top" class="description-td">202</td>
                <td morerows="0" valign="top" class="description-td">1.07</td>
                <td morerows="0" valign="top" class="description-td">0.58</td>
                <td morerows="0" valign="top" class="description-td">200</td>
                <td morerows="0" valign="top" class="description-td">3.71</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">206</td>
                <td morerows="0" valign="top" class="description-td">4.67</td>
                <td morerows="0" valign="top" class="description-td">0.72</td>
                <td morerows="0" valign="top" class="description-td">204</td>
                <td morerows="0" valign="top" class="description-td">3.91</td>
                <td morerows="0" valign="top" class="description-td">0.05</td>
                <td morerows="0" valign="top" class="description-td">206</td>
                <td morerows="0" valign="top" class="description-td">2.06</td>
                <td morerows="0" valign="top" class="description-td">0.66</td>
                <td morerows="0" valign="top" class="description-td">205</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.14</td>
                <td morerows="0" valign="top" class="description-td">206</td>
                <td morerows="0" valign="top" class="description-td">0.94</td>
                <td morerows="0" valign="top" class="description-td">0.60</td>
                <td morerows="0" valign="top" class="description-td">205</td>
                <td morerows="0" valign="top" class="description-td">3.66</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">211</td>
                <td morerows="0" valign="top" class="description-td">4.67</td>
                <td morerows="0" valign="top" class="description-td">0.72</td>
                <td morerows="0" valign="top" class="description-td">209</td>
                <td morerows="0" valign="top" class="description-td">3.92</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
                <td morerows="0" valign="top" class="description-td">211</td>
                <td morerows="0" valign="top" class="description-td">1.79</td>
                <td morerows="0" valign="top" class="description-td">0.62</td>
                <td morerows="0" valign="top" class="description-td">210</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.17</td>
                <td morerows="0" valign="top" class="description-td">212</td>
                <td morerows="0" valign="top" class="description-td">1.41</td>
                <td morerows="0" valign="top" class="description-td">1.04</td>
                <td morerows="0" valign="top" class="description-td">210</td>
                <td morerows="0" valign="top" class="description-td">3.69</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">216</td>
                <td morerows="0" valign="top" class="description-td">3.33</td>
                <td morerows="0" valign="top" class="description-td">0.72</td>
                <td morerows="0" valign="top" class="description-td">214</td>
                <td morerows="0" valign="top" class="description-td">4.09</td>
                <td morerows="0" valign="top" class="description-td">0.04</td>
                <td morerows="0" valign="top" class="description-td">216</td>
                <td morerows="0" valign="top" class="description-td">1.78</td>
                <td morerows="0" valign="top" class="description-td">0.63</td>
                <td morerows="0" valign="top" class="description-td">215</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
                <td morerows="0" valign="top" class="description-td">217</td>
                <td morerows="0" valign="top" class="description-td">0.95</td>
                <td morerows="0" valign="top" class="description-td">0.60</td>
                <td morerows="0" valign="top" class="description-td">215</td>
                <td morerows="0" valign="top" class="description-td">3.74</td>
                <td morerows="0" valign="top" class="description-td">0.09</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">221</td>
                <td morerows="0" valign="top" class="description-td">3.00</td>
                <td morerows="0" valign="top" class="description-td">0.94</td>
                <td morerows="0" valign="top" class="description-td">219</td>
                <td morerows="0" valign="top" class="description-td">4.05</td>
                <td morerows="0" valign="top" class="description-td">0.11</td>
                <td morerows="0" valign="top" class="description-td">221</td>
                <td morerows="0" valign="top" class="description-td">1.41</td>
                <td morerows="0" valign="top" class="description-td">0.58</td>
                <td morerows="0" valign="top" class="description-td">220</td>
                <td morerows="0" valign="top" class="description-td">3.87</td>
                <td morerows="0" valign="top" class="description-td">0.16</td>
                <td morerows="0" valign="top" class="description-td">221</td>
                <td morerows="0" valign="top" class="description-td">0.54</td>
                <td morerows="0" valign="top" class="description-td">0.21</td>
                <td morerows="0" valign="top" class="description-td">220</td>
                <td morerows="0" valign="top" class="description-td">3.66</td>
                <td morerows="0" valign="top" class="description-td">0.17</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">226</td>
                <td morerows="0" valign="top" class="description-td">2.17</td>
                <td morerows="0" valign="top" class="description-td">0.68</td>
                <td morerows="0" valign="top" class="description-td">224</td>
                <td morerows="0" valign="top" class="description-td">4.17</td>
                <td morerows="0" valign="top" class="description-td">0.12</td>
                <td morerows="0" valign="top" class="description-td">226</td>
                <td morerows="0" valign="top" class="description-td">0.78</td>
                <td morerows="0" valign="top" class="description-td">0.36</td>
                <td morerows="0" valign="top" class="description-td">225</td>
                <td morerows="0" valign="top" class="description-td">3.85</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
                <td morerows="0" valign="top" class="description-td">226</td>
                <td morerows="0" valign="top" class="description-td">0.72</td>
                <td morerows="0" valign="top" class="description-td">0.38</td>
                <td morerows="0" valign="top" class="description-td">225</td>
                <td morerows="0" valign="top" class="description-td">3.72</td>
                <td morerows="0" valign="top" class="description-td">0.10</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">231</td>
                <td morerows="0" valign="top" class="description-td">2.67</td>
                <td morerows="0" valign="top" class="description-td">0.98</td>
                <td morerows="0" valign="top" class="description-td">229</td>
                <td morerows="0" valign="top" class="description-td">4.00</td>
                <td morerows="0" valign="top" class="description-td">0.13</td>
                <td morerows="0" valign="top" class="description-td">231</td>
                <td morerows="0" valign="top" class="description-td">0.85</td>
                <td morerows="0" valign="top" class="description-td">0.37</td>
                <td morerows="0" valign="top" class="description-td">230</td>
                <td morerows="0" valign="top" class="description-td">3.72</td>
                <td morerows="0" valign="top" class="description-td">0.23</td>
                <td morerows="0" valign="top" class="description-td">231</td>
                <td morerows="0" valign="top" class="description-td">0.69</td>
                <td morerows="0" valign="top" class="description-td">0.38</td>
                <td morerows="0" valign="top" class="description-td">230</td>
                <td morerows="0" valign="top" class="description-td">3.75</td>
                <td morerows="0" valign="top" class="description-td">0.08</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">236</td>
                <td morerows="0" valign="top" class="description-td">2.00</td>
                <td morerows="0" valign="top" class="description-td">0.47</td>
                <td morerows="0" valign="top" class="description-td">234</td>
                <td morerows="0" valign="top" class="description-td">4.01</td>
                <td morerows="0" valign="top" class="description-td">0.05</td>
                <td morerows="0" valign="top" class="description-td">236</td>
                <td morerows="0" valign="top" class="description-td">0.76</td>
                <td morerows="0" valign="top" class="description-td">0.51</td>
                <td morerows="0" valign="top" class="description-td">235</td>
                <td morerows="0" valign="top" class="description-td">3.74</td>
                <td morerows="0" valign="top" class="description-td">0.21</td>
                <td morerows="0" valign="top" class="description-td">237</td>
                <td morerows="0" valign="top" class="description-td">0.94</td>
                <td morerows="0" valign="top" class="description-td">0.60</td>
                <td morerows="0" valign="top" class="description-td">235</td>
                <td morerows="0" valign="top" class="description-td">3.71</td>
                <td morerows="0" valign="top" class="description-td">0.03</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td">240</td>
                <td morerows="0" valign="top" class="description-td">1.17</td>
                <td morerows="0" valign="top" class="description-td">0.36</td>
                <td morerows="0" valign="top" class="description-td">239</td>
                <td morerows="0" valign="top" class="description-td">4.08</td>
                <td morerows="0" valign="top" class="description-td">0.02</td>
                <td morerows="0" valign="top" class="description-td">240</td>
                <td morerows="0" valign="top" class="description-td">1.07</td>
                <td morerows="0" valign="top" class="description-td">0.47</td>
                <td morerows="0" valign="top" class="description-td">240</td>
                <td morerows="0" valign="top" class="description-td">3.56</td>
                <td morerows="0" valign="top" class="description-td">0.18</td>
                <td morerows="0" valign="top" class="description-td">240</td>
                <td morerows="0" valign="top" class="description-td">0.88</td>
                <td morerows="0" valign="top" class="description-td">0.61</td>
                <td morerows="0" valign="top" class="description-td">240</td>
                <td morerows="0" valign="top" class="description-td">3.69</td>
                <td morerows="0" valign="top" class="description-td">0.03</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="18" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="18"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>
      <sequence-cwu id="SEQLST-1"> <sequence-list-new-rules> <s100> <s160>20</s160> </s100> <s200> <s210>1</s210> <s211>21</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 1
Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu
  1               5                  10                  15
Glu Asn Tyr Cys Asn
             20</s400> <s200> <s210>2</s210> <s211>30</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 2
Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
  1               5                  10                  15
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
             20                  25                  30</s400> <s200> <s210>3</s210> <s211>30</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 3
Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
  1               5                  10                  15
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr
             20                  25                  30</s400> <s200> <s210>4</s210> <s211>30</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 4
Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
  1               5                  10                  15
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr
             20                  25                  30</s400> <s200> <s210>5</s210> <s211>30</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 5
Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
  1               5                  10                  15
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Ile Pro Lys Thr
             20                  25                  30</s400> <s200> <s210>6</s210> <s211>97</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 6
Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His
  1               5                  10                  15
Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu
             20                  25                  30
Arg Gly Phe Phe Tyr Thr Pro Glu Thr Arg Arg Glu Ala Glu Asp Pro
         35                  40                  45
Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu
     50                  55                  60
Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu
 65                  70                  75                  80
Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys
                 85                  90                  95
Asn</s400> <s200> <s210>7</s210> <s211>97</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 7
Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His
  1               5                  10                  15
Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu
             20                  25                  30
Arg Gly Phe Phe Tyr Thr Ile Lys Thr Arg Arg Glu Ala Glu Asp Pro
         35                  40                  45
Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu
     50                  55                  60
Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu
 65                  70                  75                  80
Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys
                 85                  90                  95
Asn</s400> <s200> <s210>8</s210> <s211>97</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 8
Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His
  1               5                  10                  15
Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu
             20                  25                  30
Arg Gly Phe Phe Tyr Ile Pro Lys Thr Arg Arg Glu Ala Glu Asp Pro
         35                  40                  45
Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu
     50                  55                  60
Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu
 65                  70                  75                  80
Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys
                 85                  90                  95
Asn</s400> <s200> <s210>9</s210> <s211>21</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 9
Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu
  1               5                  10                  15
Glu Asn Tyr Cys Asp
             20</s400> <s200> <s210>10</s210> <s211>30</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 10
Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
  1               5                  10                  15
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Ile Lys Thr
             20                  25                  30</s400> <s200> <s210>11</s210> <s211>97</s211> <s212>PRT</s212> <s213>Homo sapiens</s213> </s200> <s400> 11
Met Ala Thr Thr Ser Thr Gly Asn Ser Ala Arg Phe Val Lys Gln His
  1               5                  10                  15
Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu
             20                  25                  30
Arg Gly Phe Phe Tyr Thr Ile Lys Thr Arg Arg Glu Ala Glu Asp Pro
         35                  40                  45
Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu
     50                  55                  60
Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu
 65                  70                  75                  80
Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys
                 85                  90                  95
Asp</s400> <s200> <s210>12</s210> <s211>18</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 12
tttgtgaagc agcacctg                                                   18</s400> <s200> <s210>13</s210> <s211>18</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 13
caggtgctgc ttcacaaa                                                   18</s400> <s200> <s210>14</s210> <s211>28</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 14
ttctacacac ccgagacccg cggcatcg                                        28</s400> <s200> <s210>15</s210> <s211>29</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 15
gccgcgggtc tcgggtgtgt agaagaagc                                       29</s400> <s200> <s210>16</s210> <s211>23</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 16
ttctacatcc ccaagacccg ccg                                             23</s400> <s200> <s210>17</s210> <s211>24</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 17
cttggggatg tagaagaagc ctcg                                            24</s400> <s200> <s210>18</s210> <s211>24</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 18
tacacaatca agacccgccg ggag                                            24</s400> <s200> <s210>19</s210> <s211>27</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 19
ggtcttgatt gtgtagaaga agcctcg                                         27</s400> <s200> <s210>20</s210> <s211>39</s211> <s212>DNA</s212> <s213>Homo sapiens</s213> </s200> <s400> 20
ttttttgtcg actattagtc gcagtagttc taccagctg                            39</s400> </sequence-list-new-rules> </sequence-cwu> </p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3758683">US3758683</a></td><td class="patent-data-table-td patent-date-value">Apr 30, 1971</td><td class="patent-data-table-td patent-date-value">Sep 11, 1973</td><td class="patent-data-table-td ">Jackson R</td><td class="patent-data-table-td ">Insulin product</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3868358">US3868358</a></td><td class="patent-data-table-td patent-date-value">Mar 2, 1973</td><td class="patent-data-table-td patent-date-value">Feb 25, 1975</td><td class="patent-data-table-td ">Lilly Co Eli</td><td class="patent-data-table-td ">Protamine-insulin product</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4614730">US4614730</a></td><td class="patent-data-table-td patent-date-value">Jul 31, 1984</td><td class="patent-data-table-td patent-date-value">Sep 30, 1986</td><td class="patent-data-table-td ">Novo Industri A/S</td><td class="patent-data-table-td ">Using phospholipids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4644057">US4644057</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 1985</td><td class="patent-data-table-td patent-date-value">Feb 17, 1987</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Process for the cleavage of peptides and proteins at the methionyl bond using cyanogen chloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4731405">US4731405</a></td><td class="patent-data-table-td patent-date-value">Nov 28, 1986</td><td class="patent-data-table-td patent-date-value">Mar 15, 1988</td><td class="patent-data-table-td ">Bayer Aktiengesellschaft</td><td class="patent-data-table-td ">Thermoplastic moulding materials with high tracking resistance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4783441">US4783441</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 1983</td><td class="patent-data-table-td patent-date-value">Nov 8, 1988</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Aqueous protein solutions stable to denaturation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4885164">US4885164</a></td><td class="patent-data-table-td patent-date-value">Dec 22, 1987</td><td class="patent-data-table-td patent-date-value">Dec 5, 1989</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Aqueous protein solutions stable to denaturation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5101013">US5101013</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 1988</td><td class="patent-data-table-td patent-date-value">Mar 31, 1992</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Such as those obtained by enzymatic cleavage of proinsulin, ion exchanging</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5358857">US5358857</a></td><td class="patent-data-table-td patent-date-value">Jun 9, 1993</td><td class="patent-data-table-td patent-date-value">Oct 25, 1994</td><td class="patent-data-table-td ">The General Hospital Corp.</td><td class="patent-data-table-td ">Method of preparing fusion proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5473049">US5473049</a></td><td class="patent-data-table-td patent-date-value">Dec 1, 1993</td><td class="patent-data-table-td patent-date-value">Dec 5, 1995</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Process for obtaining proinsulin possessing correctly linked cystine bridges</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5597796">US5597796</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 7, 1994</td><td class="patent-data-table-td patent-date-value">Jan 28, 1997</td><td class="patent-data-table-td ">Novo Nordisk A/S</td><td class="patent-data-table-td ">Transdermal insulin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5663291">US5663291</a></td><td class="patent-data-table-td patent-date-value">Feb 16, 1995</td><td class="patent-data-table-td patent-date-value">Sep 2, 1997</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Process for obtaining insulin having correctly linked cystine bridges</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE2219635A1?cl=en">DE2219635A1</a></td><td class="patent-data-table-td patent-date-value">Apr 21, 1972</td><td class="patent-data-table-td patent-date-value">Nov 9, 1972</td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE3240177A1?cl=en">DE3240177A1</a></td><td class="patent-data-table-td patent-date-value">Oct 29, 1982</td><td class="patent-data-table-td patent-date-value">May 11, 1983</td><td class="patent-data-table-td ">Novo Industri As</td><td class="patent-data-table-td ">Stabilisierte insulinpraeparate und verfahren zur herstellung derselben</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0018609A1?cl=en">EP0018609A1</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 1980</td><td class="patent-data-table-td patent-date-value">Nov 12, 1980</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0180920A2?cl=en">EP0180920A2</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 1985</td><td class="patent-data-table-td patent-date-value">May 14, 1986</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Process for cleaving the methionyl link of peptides and proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0211299A2?cl=en">EP0211299A2</a></td><td class="patent-data-table-td patent-date-value">Jul 19, 1986</td><td class="patent-data-table-td patent-date-value">Feb 25, 1987</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Fusion proteins, method for their production and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0214826A2?cl=en">EP0214826A2</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 1986</td><td class="patent-data-table-td patent-date-value">Mar 18, 1987</td><td class="patent-data-table-td ">Novo Nordisk A/S</td><td class="patent-data-table-td ">Insulin analogues and method of preparing the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0227938A2?cl=en">EP0227938A2</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 1986</td><td class="patent-data-table-td patent-date-value">Jul 8, 1987</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Eucaryotic fusion proteins, their preparation and use, and agents for carrying out the process</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0229956A1?cl=en">EP0229956A1</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 1986</td><td class="patent-data-table-td patent-date-value">Jul 29, 1987</td><td class="patent-data-table-td ">Bayer Ag</td><td class="patent-data-table-td ">Thermoplastic moulding materials with high track resistance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0305760A2?cl=en">EP0305760A2</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 1988</td><td class="patent-data-table-td patent-date-value">Mar 8, 1989</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Method of isolating basic proteins from a protein mixture</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0375437A2?cl=en">EP0375437A2</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 1989</td><td class="patent-data-table-td patent-date-value">Jun 27, 1990</td><td class="patent-data-table-td ">Novo Nordisk A/S</td><td class="patent-data-table-td ">Human insulin analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0419504A1?cl=en">EP0419504A1</a></td><td class="patent-data-table-td patent-date-value">May 10, 1989</td><td class="patent-data-table-td patent-date-value">Apr 3, 1991</td><td class="patent-data-table-td ">Novo Nordisk As</td><td class="patent-data-table-td ">Insulin analogues.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0600372A1?cl=en">EP0600372A1</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 1993</td><td class="patent-data-table-td patent-date-value">Jun 8, 1994</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Process for the preparation of proinsulin with correctly linked cystin bridges</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0668292A2?cl=en">EP0668292A2</a></td><td class="patent-data-table-td patent-date-value">Feb 9, 1995</td><td class="patent-data-table-td patent-date-value">Aug 23, 1995</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Process to obtain insulin with correct cystin bridges</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0678522A1?cl=en">EP0678522A1</a></td><td class="patent-data-table-td patent-date-value">Feb 6, 1990</td><td class="patent-data-table-td patent-date-value">Oct 25, 1995</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Insulin analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1983000288A1?cl=en">WO1983000288A1</a></td><td class="patent-data-table-td patent-date-value">Jul 16, 1982</td><td class="patent-data-table-td patent-date-value">Feb 3, 1983</td><td class="patent-data-table-td ">Nordisk Insulinlab</td><td class="patent-data-table-td ">A stable aqueous, therapeutic insulin preparation and a process for preparing it</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990007522A1?cl=en">WO1990007522A1</a></td><td class="patent-data-table-td patent-date-value">Dec 15, 1989</td><td class="patent-data-table-td patent-date-value">Jul 12, 1990</td><td class="patent-data-table-td ">Novo Nordisk As</td><td class="patent-data-table-td ">Human insulin analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1992000321A1?cl=en">WO1992000321A1</a></td><td class="patent-data-table-td patent-date-value">Jun 21, 1991</td><td class="patent-data-table-td patent-date-value">Jan 9, 1992</td><td class="patent-data-table-td ">Novo Nordisk As</td><td class="patent-data-table-td ">Novel, protracted insulin analogues</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Berger, Michael, "<a href='http://scholar.google.com/scholar?q="Towards+more+physiological+insulin+therapy+in+the+1990s-A+comment%2C"'>Towards more physiological insulin therapy in the 1990s-A comment,</a>" Diabetes Research and Clinical Practice, 6 (1989), pp. S25-S31.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Berger, Michael, "<a href='http://scholar.google.com/scholar?q="Towards+more+physiological+insulin+therapy+in+the+1990s%E2%80%94A+comment%2C"'>Towards more physiological insulin therapy in the 1990s—A comment,</a>" Diabetes Research and Clinical Practice, 6 (1989), pp. S25-S31.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bolli, Geremia B., "<a href='http://scholar.google.com/scholar?q="The+pharmacokinetic+basis+of+insulin+therapy+in+diabetes+mellitus%2C"'>The pharmacokinetic basis of insulin therapy in diabetes mellitus,</a>" Diabetes Research and Clinical Practice, 6 (1989), pp. S3-S16.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dixon, Dr. G.H. et al., "<a href='http://scholar.google.com/scholar?q="Regeneration+of+Insulin+Activity+From+the+Separated+and+Inactive+A+and+B+Chains%2C"'>Regeneration of Insulin Activity From the Separated and Inactive A and B Chains,</a>" Nature, vol. 188, No. 4752 (1960), pp. 721-724.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Drury, P.L. et al., "<a href='http://scholar.google.com/scholar?q="Diabetic+nephropathy%2C"'>Diabetic nephropathy,</a>" British Medical Bulletin, vol. 45, No. 1, (1989), pp 127-147.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">European Search Report for EP Application 98110889.7-2105, Oct. 14, 1998.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">German Search Report for Appln. No. 19726167.1, Nov. 24, 1997.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Home, P.D. et al., "<a href='http://scholar.google.com/scholar?q="Insuln+treatment%3A+a+decade+of+change%2C"'>Insuln treatment: a decade of change,</a>" British Medical Bulletin, vol. 45, No. 1, (1989), pp. 92-110.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kang, Steven et al., "<a href='http://scholar.google.com/scholar?q="Subcutaneous+Insulin+Absorption+Explained+by+Insulin%27s+Physicochemical+Properties-Evidence+from+Absorption+Studies+of+Soluble+Human+Insulin+and+Insulin+Analogues+in+Humans%2C"'>Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties-Evidence from Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans,</a>" Diabetes Care, vol. 14, No. 11, (1991), pp. 942-948.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kang, Steven et al., "<a href='http://scholar.google.com/scholar?q="Subcutaneous+Insulin+Absorption+Explained+by+Insulin%27s+Physicochemical+Properties%E2%80%94Evidence+from+Absorption+Studies+of+Soluble+Human+Insulin+and+Insulin+Analogues+in+Humans%2C"'>Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties—Evidence from Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans,</a>" Diabetes Care, vol. 14, No. 11, (1991), pp. 942-948.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kemmler, Wolfgang et al., "<a href='http://scholar.google.com/scholar?q="Studies+on+the+Conversion+of+Proinsulin+to+Insulin%2C"'>Studies on the Conversion of Proinsulin to Insulin,</a>" The Journal of Biological Chemistry, vol. 246, No. 22, (1971), pp. 6786-6791.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kohner, E.M., "<a href='http://scholar.google.com/scholar?q="Diabetic+retinopathy%2C"'>Diabetic retinopathy,</a>" British Medical Bulletin,vol. 45, No. 1, (1989), pp. 148-173.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Müller et al., "<a href='http://scholar.google.com/scholar?q="Insulin+Signaling+in+the+Yeast+Saccharomyces+cerevisiae+1.+Stimulation+of+Glucose+Metabolism+and+Snf+1+Kinase+by+Human+Insulin%2C"'>Insulin Signaling in the Yeast Saccharomyces cerevisiae 1. Stimulation of Glucose Metabolism and Snf 1 Kinase by Human Insulin,</a>" Biochemistry, vol. 37, No. 24, (1998), pp. 8683-8695.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nathan. et al., "<a href='http://scholar.google.com/scholar?q="The+Effect+of+Intensive+Treatment+of+Diabetes+on+the+Development+and+Progression+of+Long-Term+Complications+in+Insulin-Dependent+Diabetes+Mellitus%2C"'>The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus,</a>" The New England Journal of Medicine, vol. 329, No. 14, (1993), pp. 977-986.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ward, J.D., "<a href='http://scholar.google.com/scholar?q="Diabetic+neuropathy%2C"'>Diabetic neuropathy,</a>" British Medical Bulletin, vol. 45, No. 1, (1989), pp. 111-126.</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6624185">US6624185</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2002</td><td class="patent-data-table-td patent-date-value">Sep 23, 2003</td><td class="patent-data-table-td ">Aventis Pharma Deutschland Gmbh</td><td class="patent-data-table-td ">Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6884812">US6884812</a></td><td class="patent-data-table-td patent-date-value">Aug 1, 2003</td><td class="patent-data-table-td patent-date-value">Apr 26, 2005</td><td class="patent-data-table-td ">Aventis Pharma Deutschland Gmbh</td><td class="patent-data-table-td ">Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7008957">US7008957</a></td><td class="patent-data-table-td patent-date-value">Jul 26, 2004</td><td class="patent-data-table-td patent-date-value">Mar 7, 2006</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">6-amino-5-oxo--hexahydropyrrolo[2,1-b]thiazole-3-carbonitrile compounds of given formula; for the treatment of metabohlic disorders such as type 2 diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7049341">US7049341</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2003</td><td class="patent-data-table-td patent-date-value">May 23, 2006</td><td class="patent-data-table-td ">Aventis Pharma Deutschland Gmbh</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7078404">US7078404</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2003</td><td class="patent-data-table-td patent-date-value">Jul 18, 2006</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7094794">US7094794</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 2004</td><td class="patent-data-table-td patent-date-value">Aug 22, 2006</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">used for lowering the blood glucose and for the prevention and treatment of diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7094800">US7094800</a></td><td class="patent-data-table-td patent-date-value">Jul 26, 2004</td><td class="patent-data-table-td patent-date-value">Aug 22, 2006</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">pyrrolizinones, e.g., (3S,6R,7aS)-6-amino-5-oxo-hexahydro-pyrrolizine-3-carbonitrile trifluoroacetate, used for reducing blood sugar, treating type 2 diabetes, and treating insulin resistance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7101856">US7101856</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2003</td><td class="patent-data-table-td patent-date-value">Sep 5, 2006</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7138414">US7138414</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2003</td><td class="patent-data-table-td patent-date-value">Nov 21, 2006</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7148246">US7148246</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">Dec 12, 2006</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Therapy, prevention diseases of fatty acid metabolism, glucose utilization; insulin resistance; antidiabetic agents; antilipemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7160911">US7160911</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">Jan 9, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7173151">US7173151</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">Feb 6, 2007</td><td class="patent-data-table-td ">Sanofi-Aventisdeutschand Gmbh</td><td class="patent-data-table-td ">Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7179788">US7179788</a></td><td class="patent-data-table-td patent-date-value">Oct 7, 2002</td><td class="patent-data-table-td patent-date-value">Feb 20, 2007</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Synergistic mixtur eof glucangon-like peptide , in solid phase, and insulin solution, in liquid phase; antidiabetic agents; obesity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7179792">US7179792</a></td><td class="patent-data-table-td patent-date-value">Nov 3, 2003</td><td class="patent-data-table-td patent-date-value">Feb 20, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deulschland Gmbh</td><td class="patent-data-table-td ">Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least one other active ingredient and the use of the product</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7179941">US7179941</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 2004</td><td class="patent-data-table-td patent-date-value">Feb 20, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">N-{3-[3-(2-Chloro-4,5-difluorobenzoyl)ureido]-4-methoxyphenyl}acetamide; treating type 2 diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7193035">US7193035</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 29, 2003</td><td class="patent-data-table-td patent-date-value">Mar 20, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Asparagine in position B3 and lysine in position B29 are replaced by lysine and glutamic acid, respectively; inhalant and oral dosage forms; dissolving and purifying the amorphous powder; antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7196114">US7196114</a></td><td class="patent-data-table-td patent-date-value">Feb 17, 2004</td><td class="patent-data-table-td patent-date-value">Mar 27, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7205290">US7205290</a></td><td class="patent-data-table-td patent-date-value">Mar 31, 2004</td><td class="patent-data-table-td patent-date-value">Apr 17, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7208504">US7208504</a></td><td class="patent-data-table-td patent-date-value">Oct 14, 2003</td><td class="patent-data-table-td patent-date-value">Apr 24, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Bicyclic inhibitors of hormone sensitive lipase</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7220876">US7220876</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">May 22, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7223796">US7223796</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2003</td><td class="patent-data-table-td patent-date-value">May 29, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7238663">US7238663</a></td><td class="patent-data-table-td patent-date-value">Aug 23, 2002</td><td class="patent-data-table-td patent-date-value">Jul 3, 2007</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Comprising a GLP-1 compound and an acylated basal insulin or a pI shifted basal insulin; can be used to treat diseases such as non-insulin dependent diabetes mellitus and insulin dependent diabetes mellitus, hyperglycemia, obesity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7241787">US7241787</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2005</td><td class="patent-data-table-td patent-date-value">Jul 10, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7259177">US7259177</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">Aug 21, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Containing an oxazole ring 2-phenyl-, furanyl- or thiophenyl-substituted; e.g., 2,2-Dimethyl-4-[3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]-butyric acid; treating disorders of fatty acid metabolism, glucose utilization disorders, and also of disorders in which insulin resistance is involvolved</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7262220">US7262220</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2003</td><td class="patent-data-table-td patent-date-value">Aug 28, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7288528">US7288528</a></td><td class="patent-data-table-td patent-date-value">Dec 12, 2003</td><td class="patent-data-table-td patent-date-value">Oct 30, 2007</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7335671">US7335671</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">Feb 26, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">containing a 2-(hetero)aryloxazol-4-ylalkylcycloalkyl group, (2R/2S)-3-[(1R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxymethyl)-cyclohexyloxy ]-2-(4-trifluoromethylbenzyloxy)propionic acid; treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization and insulin resistance;</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7365084">US7365084</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">Apr 29, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7378440">US7378440</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 2004</td><td class="patent-data-table-td patent-date-value">May 27, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Antidiabetic agents; therapy for insulin resistance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7387996">US7387996</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Jun 17, 2008</td><td class="patent-data-table-td ">Novo Nordisk A/S</td><td class="patent-data-table-td ">Stable insulin formulations prepared by mixing a monomeric insulin and a soluble acylated insulin analog; especially suited for use in an infusion system; superior long-term physical stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7399777">US7399777</a></td><td class="patent-data-table-td patent-date-value">Apr 4, 2005</td><td class="patent-data-table-td patent-date-value">Jul 15, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7402674">US7402674</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2005</td><td class="patent-data-table-td patent-date-value">Jul 22, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh,</td><td class="patent-data-table-td ">antidiabetic agents; type 2 diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7452860">US7452860</a></td><td class="patent-data-table-td patent-date-value">Mar 8, 2007</td><td class="patent-data-table-td patent-date-value">Nov 18, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Zinc-free and low-zinc insulin preparations having improved stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7470706">US7470706</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2005</td><td class="patent-data-table-td patent-date-value">Dec 30, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7498341">US7498341</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2005</td><td class="patent-data-table-td patent-date-value">Mar 3, 2009</td><td class="patent-data-table-td ">Sanofi Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7501440">US7501440</a></td><td class="patent-data-table-td patent-date-value">Mar 8, 2004</td><td class="patent-data-table-td patent-date-value">Mar 10, 2009</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">blood sugar-reducing action; inhibit the activity of glycogen phosphorylase</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7528155">US7528155</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2005</td><td class="patent-data-table-td patent-date-value">May 5, 2009</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">1H-Indazol-3-yl 4-methylpiperidine-1-carboxylate; synergistic mixture with antidiabetic agent, lipid modulators, and other active ingredients for the treatment of disorders of fatty acid metabolism, glucose utilization, and insulin resistance disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7666848">US7666848</a></td><td class="patent-data-table-td patent-date-value">Aug 14, 2006</td><td class="patent-data-table-td patent-date-value">Feb 23, 2010</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7696162">US7696162</a></td><td class="patent-data-table-td patent-date-value">Oct 6, 2008</td><td class="patent-data-table-td patent-date-value">Apr 13, 2010</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Contains a surfactant and a preservative, an isotonicizing agent, a buffer, and/or an excipient; has less than 0.2% by weight of zinc based on the insulin content of the formulation; Polypeptide mixture; treating diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7737144">US7737144</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2007</td><td class="patent-data-table-td patent-date-value">Jun 15, 2010</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">1-Ethyl-6-methyl-3-phenyl-1H-pyrinido[5,4-e]1,2,4]triazine-5,7-dione, used for lowering blood sugar, treating non-insulin dependent diabetes and insulin resistance; antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7772429">US7772429</a></td><td class="patent-data-table-td patent-date-value">Mar 26, 2007</td><td class="patent-data-table-td patent-date-value">Aug 10, 2010</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">chemical intermediate 11-((4R,6R)-4,5,6-trihydroxy-3-(R)-hydroxy-2-(S)-hydroxyhexylcarbamoyl)undecanoic acid; for making antilipemic agents; anticholesterol agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7781459">US7781459</a></td><td class="patent-data-table-td patent-date-value">Dec 20, 2006</td><td class="patent-data-table-td patent-date-value">Aug 24, 2010</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7829081">US7829081</a></td><td class="patent-data-table-td patent-date-value">Mar 4, 2010</td><td class="patent-data-table-td patent-date-value">Nov 9, 2010</td><td class="patent-data-table-td ">Halozyme, Inc.</td><td class="patent-data-table-td ">Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7846431">US7846431</a></td><td class="patent-data-table-td patent-date-value">Mar 4, 2010</td><td class="patent-data-table-td patent-date-value">Dec 7, 2010</td><td class="patent-data-table-td ">Halozyme, Inc.</td><td class="patent-data-table-td ">Composition comprising hyaluronidase glycoprotein that is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine for use in treatment of diabetic disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7872034">US7872034</a></td><td class="patent-data-table-td patent-date-value">Jan 14, 2008</td><td class="patent-data-table-td patent-date-value">Jan 18, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8003636">US8003636</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2008</td><td class="patent-data-table-td patent-date-value">Aug 23, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8048901">US8048901</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 2007</td><td class="patent-data-table-td patent-date-value">Nov 1, 2011</td><td class="patent-data-table-td ">Aventis Pharma Deutschland Gmbh</td><td class="patent-data-table-td ">5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8063221">US8063221</a></td><td class="patent-data-table-td patent-date-value">Mar 13, 2007</td><td class="patent-data-table-td patent-date-value">Nov 22, 2011</td><td class="patent-data-table-td ">Kyorin Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Aminoquinolones as GSK-3 inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8071591">US8071591</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2010</td><td class="patent-data-table-td patent-date-value">Dec 6, 2011</td><td class="patent-data-table-td ">Kyorin Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">7-cycloalkylaminoquinolones as GSK-3 inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8192957">US8192957</a></td><td class="patent-data-table-td patent-date-value">Apr 6, 2009</td><td class="patent-data-table-td patent-date-value">Jun 5, 2012</td><td class="patent-data-table-td ">Case Western Reserve University</td><td class="patent-data-table-td ">Fibrillation-resistant insulin and insulin analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8247452">US8247452</a></td><td class="patent-data-table-td patent-date-value">Aug 27, 2007</td><td class="patent-data-table-td patent-date-value">Aug 21, 2012</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Urea- and urethane-substituted acylureas, process for their preparation and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8318154">US8318154</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2009</td><td class="patent-data-table-td patent-date-value">Nov 27, 2012</td><td class="patent-data-table-td ">Halozyme, Inc.</td><td class="patent-data-table-td ">Super fast-acting insulin compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8343914">US8343914</a></td><td class="patent-data-table-td patent-date-value">Jan 8, 2007</td><td class="patent-data-table-td patent-date-value">Jan 1, 2013</td><td class="patent-data-table-td ">Case Western Reserve University</td><td class="patent-data-table-td ">Fibrillation resistant proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8389514">US8389514</a></td><td class="patent-data-table-td patent-date-value">Sep 11, 2008</td><td class="patent-data-table-td patent-date-value">Mar 5, 2013</td><td class="patent-data-table-td ">Kyorin Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8399407">US8399407</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 2010</td><td class="patent-data-table-td patent-date-value">Mar 19, 2013</td><td class="patent-data-table-td ">Case Western Reserve University</td><td class="patent-data-table-td ">Non-standard insulin analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8476261">US8476261</a></td><td class="patent-data-table-td patent-date-value">Sep 12, 2008</td><td class="patent-data-table-td patent-date-value">Jul 2, 2013</td><td class="patent-data-table-td ">Kyorin Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Spirocyclic aminoquinolones as GSK-3 inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8501440">US8501440</a></td><td class="patent-data-table-td patent-date-value">May 16, 2012</td><td class="patent-data-table-td patent-date-value">Aug 6, 2013</td><td class="patent-data-table-td ">Case Western Reserve University</td><td class="patent-data-table-td ">Fibrillation-resistant insulin and insulin analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8568713">US8568713</a></td><td class="patent-data-table-td patent-date-value">May 18, 2012</td><td class="patent-data-table-td patent-date-value">Oct 29, 2013</td><td class="patent-data-table-td ">Halozyme, Inc.</td><td class="patent-data-table-td ">Super fast-acting insulin compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8623379">US8623379</a></td><td class="patent-data-table-td patent-date-value">Jan 3, 2003</td><td class="patent-data-table-td patent-date-value">Jan 7, 2014</td><td class="patent-data-table-td ">Emory University</td><td class="patent-data-table-td ">Compositions and methods for generating an immune response</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8748483">US8748483</a></td><td class="patent-data-table-td patent-date-value">Jul 16, 2009</td><td class="patent-data-table-td patent-date-value">Jun 10, 2014</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102007002260A1?cl=en">DE102007002260A1</a></td><td class="patent-data-table-td patent-date-value">Jan 16, 2007</td><td class="patent-data-table-td patent-date-value">Jul 31, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis</td><td class="patent-data-table-td ">Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102007005045A1?cl=en">DE102007005045A1</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2007</td><td class="patent-data-table-td patent-date-value">Aug 7, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis</td><td class="patent-data-table-td ">New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102007008420A1?cl=en">DE102007008420A1</a></td><td class="patent-data-table-td patent-date-value">Feb 21, 2007</td><td class="patent-data-table-td patent-date-value">Aug 28, 2008</td><td class="patent-data-table-td ">Merck Patent Gmbh</td><td class="patent-data-table-td ">Benzimidazolderivate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102007048716A1?cl=en">DE102007048716A1</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2007</td><td class="patent-data-table-td patent-date-value">Apr 23, 2009</td><td class="patent-data-table-td ">Merck Patent Gmbh</td><td class="patent-data-table-td ">Imidazo[1,2-a]pyrimidinderivate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102007063671A1?cl=en">DE102007063671A1</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2007</td><td class="patent-data-table-td patent-date-value">Jun 25, 2009</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102008017590A1?cl=en">DE102008017590A1</a></td><td class="patent-data-table-td patent-date-value">Apr 7, 2008</td><td class="patent-data-table-td patent-date-value">Oct 8, 2009</td><td class="patent-data-table-td ">Merck Patent Gmbh</td><td class="patent-data-table-td ">Glucopyranosidderivate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102010015123A1?cl=en">DE102010015123A1</a></td><td class="patent-data-table-td patent-date-value">Apr 16, 2010</td><td class="patent-data-table-td patent-date-value">Oct 20, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2083006A1?cl=en">EP2083006A1</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2005</td><td class="patent-data-table-td patent-date-value">Jul 29, 2009</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland GmbH</td><td class="patent-data-table-td ">Oxadiazolones, processes for their preparation and their use as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2138176A1?cl=en">EP2138176A1</a></td><td class="patent-data-table-td patent-date-value">Apr 1, 2005</td><td class="patent-data-table-td patent-date-value">Dec 30, 2009</td><td class="patent-data-table-td ">Aventis Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Method of treating cognitive impairment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2383271A1?cl=en">EP2383271A1</a></td><td class="patent-data-table-td patent-date-value">Mar 13, 2007</td><td class="patent-data-table-td patent-date-value">Nov 2, 2011</td><td class="patent-data-table-td ">Kyorin Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Aminoquinolones as GSK-3 Inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2567959A1?cl=en">EP2567959A1</a></td><td class="patent-data-table-td patent-date-value">Sep 12, 2011</td><td class="patent-data-table-td patent-date-value">Mar 13, 2013</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004072025A2?cl=en">WO2004072025A2</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2004</td><td class="patent-data-table-td patent-date-value">Aug 26, 2004</td><td class="patent-data-table-td ">Aventis Pharma Gmbh</td><td class="patent-data-table-td ">Substituted n-arylheterocycles, method for production and use thereof as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004075815A2?cl=en">WO2004075815A2</a></td><td class="patent-data-table-td patent-date-value">Feb 19, 2004</td><td class="patent-data-table-td patent-date-value">Sep 10, 2004</td><td class="patent-data-table-td ">Aventis Pharma Gmbh</td><td class="patent-data-table-td ">Diarylcycloalkyl derivatives, method for their production and their use as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006131231A1?cl=en">WO2006131231A1</a></td><td class="patent-data-table-td patent-date-value">May 27, 2006</td><td class="patent-data-table-td patent-date-value">Dec 14, 2006</td><td class="patent-data-table-td ">Sanofi Aventis Deutschland</td><td class="patent-data-table-td ">Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007147478A1?cl=en">WO2007147478A1</a></td><td class="patent-data-table-td patent-date-value">May 25, 2007</td><td class="patent-data-table-td patent-date-value">Dec 27, 2007</td><td class="patent-data-table-td ">Merck Patent Gmbh</td><td class="patent-data-table-td ">3 -amino-imidazo[1, 2-a]pyridine derivatives as sglt inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008017381A1?cl=en">WO2008017381A1</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2007</td><td class="patent-data-table-td patent-date-value">Feb 14, 2008</td><td class="patent-data-table-td ">Sanofi Aventis</td><td class="patent-data-table-td ">Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009021740A2?cl=en">WO2009021740A2</a></td><td class="patent-data-table-td patent-date-value">Aug 14, 2008</td><td class="patent-data-table-td patent-date-value">Feb 19, 2009</td><td class="patent-data-table-td ">Sanofis Aventis</td><td class="patent-data-table-td ">Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009049731A1?cl=en">WO2009049731A1</a></td><td class="patent-data-table-td patent-date-value">Sep 13, 2008</td><td class="patent-data-table-td patent-date-value">Apr 23, 2009</td><td class="patent-data-table-td ">Merck Patent Gmbh</td><td class="patent-data-table-td ">Imidazo[1,2-a]pyrimidine derivatives for treating diseases such as diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009124638A1?cl=en">WO2009124638A1</a></td><td class="patent-data-table-td patent-date-value">Mar 17, 2009</td><td class="patent-data-table-td patent-date-value">Oct 15, 2009</td><td class="patent-data-table-td ">Merck Patent Gmbh</td><td class="patent-data-table-td ">Glucopyranoside derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009129250A2?cl=en">WO2009129250A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 14, 2009</td><td class="patent-data-table-td patent-date-value">Oct 22, 2009</td><td class="patent-data-table-td ">Case Western Reserve University</td><td class="patent-data-table-td ">Meal-time insulin analogues of enhanced stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010003624A2?cl=en">WO2010003624A2</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 2009</td><td class="patent-data-table-td patent-date-value">Jan 14, 2010</td><td class="patent-data-table-td ">Sanofi-Aventis</td><td class="patent-data-table-td ">Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010068601A1?cl=en">WO2010068601A1</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 2009</td><td class="patent-data-table-td patent-date-value">Jun 17, 2010</td><td class="patent-data-table-td ">Sanofi-Aventis</td><td class="patent-data-table-td ">A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011039338A2?cl=en">WO2011039338A2</a></td><td class="patent-data-table-td patent-date-value">Oct 1, 2010</td><td class="patent-data-table-td patent-date-value">Apr 7, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis</td><td class="patent-data-table-td ">Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011107494A1?cl=en">WO2011107494A1</a></td><td class="patent-data-table-td patent-date-value">Mar 2, 2011</td><td class="patent-data-table-td patent-date-value">Sep 9, 2011</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011161030A1?cl=en">WO2011161030A1</a></td><td class="patent-data-table-td patent-date-value">Jun 20, 2011</td><td class="patent-data-table-td patent-date-value">Dec 29, 2011</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012004269A1?cl=en">WO2012004269A1</a></td><td class="patent-data-table-td patent-date-value">Jul 5, 2011</td><td class="patent-data-table-td patent-date-value">Jan 12, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">(2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012004270A1?cl=en">WO2012004270A1</a></td><td class="patent-data-table-td patent-date-value">Jul 5, 2011</td><td class="patent-data-table-td patent-date-value">Jan 12, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012010413A1?cl=en">WO2012010413A1</a></td><td class="patent-data-table-td patent-date-value">Jul 5, 2011</td><td class="patent-data-table-td patent-date-value">Jan 26, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012098462A1?cl=en">WO2012098462A1</a></td><td class="patent-data-table-td patent-date-value">Jan 20, 2012</td><td class="patent-data-table-td patent-date-value">Jul 26, 2012</td><td class="patent-data-table-td ">Zealand Pharma A/S</td><td class="patent-data-table-td ">Combination of acylated glucagon analogues with insulin analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120050A1?cl=en">WO2012120050A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120051A1?cl=en">WO2012120051A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120052A1?cl=en">WO2012120052A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120053A1?cl=en">WO2012120053A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120054A1?cl=en">WO2012120054A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120055A1?cl=en">WO2012120055A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120056A1?cl=en">WO2012120056A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120057A1?cl=en">WO2012120057A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120058A1?cl=en">WO2012120058A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S069400">435/69.4</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S303000">530/303</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S243000">435/243</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S320100">435/320.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S023100">536/23.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S325000">435/325</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S866000">514/866</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S023510">536/23.51</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S006100">514/6.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S006300">514/6.3</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S005900">514/5.9</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S006200">514/6.2</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0001210000">C12N1/21</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014620000">C07K14/62</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12R0001190000">C12R1/19</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038000000">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0001150000">C12N1/15</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0001190000">C12N1/19</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0005100000">C12N5/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038280000">A61K38/28</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12P0021020000">C12P21/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015090000">C12N15/09</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015620000">C12N15/62</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015170000">C12N15/17</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12R0001865000">C12R1/865</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/866">Y10S514/866</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K2319/00">C07K2319/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/00">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=viJUBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/62">C07K14/62</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07K14/62</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Sep 26, 2012</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 24, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 11, 2007</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 20, 2007</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 23, 2007</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">May 22, 2007</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1, 2, 33, 56, 59, 61 AND 63 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 3-32, 34-55, 57-58, 60, 62 AND 64, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 65 AND 66 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 14, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016891/0619</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050728</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 22, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016800/0538</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050728</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SANOFI-AVENTIS DEUTSCHLAND GMBH,GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;US-ASSIGNMENT DATABASE UPDATED:20100309;REEL/FRAME:16800/538</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;US-ASSIGNMENT DATABASE UPDATED:20100302;REEL/FRAME:16800/538</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050901</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SANOFI-AVENTIS DEUTSCHLAND GMBH,GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;US-ASSIGNMENT DATABASE UPDATED:20100406;REEL/FRAME:16793/789</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;US-ASSIGNMENT DATABASE UPDATED:20100504;REEL/FRAME:16793/789</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:16793/789</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 16, 2004</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 16, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040202</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 5, 2002</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 18, 2000</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS PHARMA DEUTSCHLAND GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:HOECHST MARION ROUSSEL DEUTSCHLAND GMBH;REEL/FRAME:011019/0234</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20000204</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS PHARMA DEUTSCHLAND GMBH INDUSTRIEPARK HOCH</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 14, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">HOECHST MARION ROUSSEL DEUTSCHLAND GMBH, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ERTL, JOHANN;HABERMANN, PAUL;GEISEN, KARL;AND OTHERS;REEL/FRAME:009506/0440</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19980630</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U1ZcO4Mw5D_5i9UvuVjP8WO4naCTw\u0026id=viJUBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U3QvxMAzeJ9_wFPcS9rc4OocWH-Tw\u0026id=viJUBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U1ndHIid6JR6GWwXylA5-Ph3O9Vbg","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Insulin_derivatives_having_a_rapid_onset.pdf?id=viJUBAABERAJ\u0026output=pdf\u0026sig=ACfU3U26OwpK3KPqWP7zfvDnjgM90PLx3Q"},"sample_url":"http://www.google.com/patents/reader?id=viJUBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>